{"1c48d5ef32cc45da3fb5e850b995640f22276135": [["IntroductionThe novel Coronavirus disease 2019 outbreak in Wuhan, China, evolved rapidly into a pandemic with businesses, governments, and international organizations taking unprecedented actions to limit this threat to global health.", [["Coronavirus disease", "DISEASE", 22, 41], ["The novel Coronavirus disease", "PROBLEM", 12, 41], ["Coronavirus disease", "OBSERVATION", 22, 41]]], ["At individual level, the Covid-19 pandemic presented several challenges ranging from fear of infection by a poorly understood illness with unclear prognosis to limited possibilities of diagnostics and shortage of personal protection equipment (1) .", [["infection", "DISEASE", 93, 102], ["the Covid", "TEST", 21, 30], ["infection", "PROBLEM", 93, 102], ["personal protection equipment", "TREATMENT", 213, 242], ["infection", "OBSERVATION", 93, 102]]], ["Furthermore, actions to curb the spread of Covid-19 led to implementation of unfamiliar public health measures such as social isolation and distancing, remote education and work, ban of travel and concerns about job security and financial sustainability (2) .", [["Covid", "TEST", 43, 48], ["unfamiliar public health measures", "TREATMENT", 77, 110], ["social isolation", "TREATMENT", 119, 135]]], ["For example, up to 33% of the surveyed participants reported increased worries during the swine flu in the UK (6) , 48% of the general population demonstrated depressive symptoms during Ebola outbreak in Sierra Leone (7) , and 57% of subjects reported increased irritability during Severe Acute Respiratory Syndrome (SARS) outbreak in Hong Kong in 2002-2004(8) .", [["depressive symptoms", "DISEASE", 159, 178], ["Ebola", "DISEASE", 186, 191], ["irritability", "DISEASE", 262, 274], ["Acute Respiratory Syndrome", "DISEASE", 289, 315], ["SARS", "DISEASE", 317, 321], ["participants", "ORGANISM", 39, 51], ["participants", "SPECIES", 39, 51], ["swine", "SPECIES", 90, 95], ["swine flu", "SPECIES", 90, 99], ["increased worries", "PROBLEM", 61, 78], ["depressive symptoms", "PROBLEM", 159, 178], ["increased irritability", "PROBLEM", 252, 274], ["Severe Acute Respiratory Syndrome", "PROBLEM", 282, 315], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["depressive", "OBSERVATION_MODIFIER", 159, 169], ["increased", "OBSERVATION_MODIFIER", 252, 261], ["irritability", "OBSERVATION_MODIFIER", 262, 274], ["Severe", "OBSERVATION_MODIFIER", 282, 288], ["Acute", "OBSERVATION_MODIFIER", 289, 294], ["Respiratory Syndrome", "OBSERVATION", 295, 315]]], ["Although these outbreaks were geographically limited compared with Covid-19, findings from these outbreaks are consistent with those from the earliest studies assessing the impact of Covid-19 on mental health.", [["Covid-19", "CHEMICAL", 183, 191], ["Covid", "TEST", 67, 72], ["the earliest studies", "TEST", 138, 158], ["Covid", "TEST", 183, 188], ["consistent with", "UNCERTAINTY", 111, 126]]], ["These studies most commonly estimated the frequency of stress and depression either in specific populations such as healthcare professionals(9-11) or in convenience samples from regions of the world experiencing Covid-19 early in the pandemic such as China(12, 13) and Italy(14).", [["depression", "DISEASE", 66, 76], ["These studies", "TEST", 0, 13], ["stress", "PROBLEM", 55, 61], ["depression", "PROBLEM", 66, 76], ["Covid", "TEST", 212, 217]]], ["To date, only few studies described the impact of Covid-19 on general psychological distress in time (15) (16) (17) with only one containing also pre-Covid-19 data (18) .", [["psychological distress", "DISEASE", 70, 92], ["Covid", "TEST", 50, 55], ["general psychological distress", "PROBLEM", 62, 92]]], ["In summary, findings from previous outbreaks, together with the early observations from the Covid-19 pandemic, all support the hypothesis that Covid-19, in particular due to its rapid and global spread with unprecedented governmental actions, causes significant impact on the global mental health.IntroductionThis hypothesis is further corroborated by recent position papers on the impact of Covid-19 on global mental health (19, 20) , which noted that large majority of studies to date reported largely cross-sectional data from different convenience samples, which do not critically measure changes in various psychological symptoms in response to Covid-19.", [["the Covid", "TEST", 88, 97], ["Covid", "TEST", 143, 148], ["its rapid and global spread", "PROBLEM", 174, 201], ["Covid", "TEST", 392, 397], ["various psychological symptoms", "PROBLEM", 604, 634], ["Covid", "TEST", 650, 655], ["rapid", "OBSERVATION_MODIFIER", 178, 183], ["significant", "OBSERVATION_MODIFIER", 250, 261], ["impact", "OBSERVATION_MODIFIER", 262, 268], ["large", "OBSERVATION_MODIFIER", 453, 458]]], ["Moreover, risk factors and mechanisms underlying possible changes in the psychological symptoms in response to Covid-19 remain poorly understood.", [["Covid-19", "CHEMICAL", 111, 119], ["risk factors", "PROBLEM", 10, 22], ["changes in the psychological symptoms", "PROBLEM", 58, 95], ["Covid", "TEST", 111, 116]]], ["To address these gaps, we here took advantage of a wellcharacterized population-based sample representing randomly selected 1% of the population of the city of Brno, Czech Republic, to critically measure changes in stress and depression during Covid-19 longitudinally and to identify possible risk factors.", [["depression", "DISEASE", 226, 236], ["a wellcharacterized population", "TREATMENT", 49, 79], ["stress", "PROBLEM", 215, 221], ["depression", "PROBLEM", 226, 236], ["Covid", "TEST", 244, 249], ["risk factors", "PROBLEM", 293, 305]]], ["No reuse allowed without permission.Introduction(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.IntroductionThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.", [["med", "ANATOMY", 127, 130]]], ["28.20163113 doi: medRxiv preprintStudy design and study populationA summary of the baseline examination protocol and general characteristics of the populationbased sample has been published previously (21) .", [["the baseline examination protocol", "TEST", 79, 112], ["the populationbased sample", "TEST", 144, 170]]], ["Briefly, the Kardiovize study, is a prospective longitudinal epidemiological cohort that investigates cardiovascular, neuropsychiatric, and other health-related topics in Central Europe carried out on a representative randomly selected 1% The e-questionnaire consisted of several items, which were assessed during the baseline measurements of the original Kardiovize study, and included also the Perceived Stress Scale(23) (PSS) and Patient Health Questionnaire-9(24) (PHQ-9).", [["cardiovascular", "ANATOMY", 102, 116], ["cardiovascular", "ANATOMICAL_SYSTEM", 102, 116], ["Patient", "SPECIES", 433, 440], ["the Kardiovize study", "TEST", 9, 29], ["the original Kardiovize study", "TEST", 343, 372], ["Stress Scale", "TEST", 406, 418], ["Patient Health Questionnaire", "TEST", 433, 461], ["PHQ", "TEST", 469, 472]]], ["The e-questionnaire consisted in demographic characteristics, response to how Covid-19 related government measures affected their daily life and habits, including their experience with quarantine and the use of personal protective equipment, their current medical status (in the Supplement pp [2] [3] [4] [5] and psychological questionnaires evaluating stress, depressive symptoms, loneliness, and illness perception.Main outcomesPrimary outcomes were stress levels and severity of depressive symptoms.", [["depressive symptoms", "DISEASE", 361, 380], ["loneliness", "DISEASE", 382, 392], ["illness", "DISEASE", 398, 405], ["depressive symptoms", "DISEASE", 482, 501], ["personal protective equipment", "TREATMENT", 211, 240], ["psychological questionnaires", "TEST", 313, 341], ["stress", "PROBLEM", 353, 359], ["depressive symptoms", "PROBLEM", 361, 380], ["loneliness", "PROBLEM", 382, 392], ["stress levels", "TEST", 452, 465], ["depressive symptoms", "PROBLEM", 482, 501]]], ["Presence and severity of stress was assessed using PSS, presence and severity of depressive symptoms were assessed using the identical two items of PHQ-9 (before Covid-19) and PHQ-4(25) (during questionnaires.", [["depressive symptoms", "DISEASE", 81, 100], ["stress", "PROBLEM", 25, 31], ["PSS", "TREATMENT", 51, 54], ["depressive symptoms", "PROBLEM", 81, 100], ["PHQ", "TEST", 148, 151], ["Covid", "TEST", 162, 167], ["PHQ", "TEST", 176, 179]]], ["Presence of depressive symptoms was defined as the sum of the score on two PHQ items equal or greater than three(25), stress levels were categorized as low (score of 0-13), medium (score of 14-26), and high (score of [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40]Statistical analysisDescriptive statistics were conducted for the socio-demographic variables and behavioural parameters.", [["depressive symptoms", "DISEASE", 12, 31], ["[27] [28] [29] [30] [31] [32] [33] [34] [35] [36]", "CHEMICAL", 217, 266], ["[27] [28] [29] [30] [31] [32] [33] [34", "SIMPLE_CHEMICAL", 217, 255], ["depressive symptoms", "PROBLEM", 12, 31], ["two PHQ items", "TEST", 71, 84], ["stress levels", "TEST", 118, 131], ["medium (score", "TEST", 173, 186], ["Statistical analysisDescriptive statistics", "TEST", 286, 328], ["demographic variables", "TEST", 358, 379], ["behavioural parameters", "TEST", 384, 406], ["depressive", "OBSERVATION_MODIFIER", 12, 22], ["symptoms", "OBSERVATION", 23, 31]]], ["McNemar's test was used to assess differences in prevalence of nominal stress levels and presence of depressive symptoms.", [["depressive symptoms", "DISEASE", 101, 120], ["McNemar's test", "TEST", 0, 14], ["nominal stress levels", "PROBLEM", 63, 84], ["depressive symptoms", "PROBLEM", 101, 120]]], ["Gains of stress and depressive symptoms were calculated as a difference between repeated measures (Covid-19 score minus pre-Covid-19 score).Statistical analysisMissing values were identified in baseline stress (N = 13) and depressive symptoms (N = 19), representing 1.8% and 2.7% of the sample.", [["depressive symptoms", "DISEASE", 20, 39], ["depressive symptoms", "DISEASE", 223, 242], ["stress and depressive symptoms", "PROBLEM", 9, 39], ["Covid", "TEST", 99, 104], ["pre-Covid", "TEST", 120, 129], ["Statistical analysisMissing values", "TEST", 140, 174], ["depressive symptoms", "PROBLEM", 223, 242], ["the sample", "TEST", 283, 293]]], ["No missing value imputation was performed, only cases with complete pair of values were used in statistical analysis (702 cases for stress level and 696 cases for severity of depressive symptoms).", [["depressive symptoms", "DISEASE", 175, 194], ["missing value imputation", "PROBLEM", 3, 27], ["statistical analysis", "TEST", 96, 116], ["stress level", "TEST", 132, 144], ["depressive symptoms", "PROBLEM", 175, 194]]], ["The missing data were completely at random, non-overlapping in cases, with no observable pattern in their distribution in relation to sex, age, or education.", [["no observable", "UNCERTAINTY", 75, 88]]], ["There were no significant differences in mean scores of stress levels and severity of depressive symptoms between participants with and without baseline missing values (see eTable 1 in Supplement).", [["depressive symptoms", "DISEASE", 86, 105], ["participants", "SPECIES", 114, 126], ["stress levels", "PROBLEM", 56, 69], ["depressive symptoms", "PROBLEM", 86, 105], ["baseline missing values", "PROBLEM", 144, 167], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["The population included all participants of Kardiovize study who completed the Covid-19 add-on study e-questionnaire.", [["participants", "SPECIES", 28, 40], ["Kardiovize study", "TEST", 44, 60]]], ["No sample-size calculations were performed.Statistical analysisAll rights reserved.", [["sample-size calculations", "TEST", 3, 27], ["Statistical analysis", "TEST", 43, 63], ["size", "OBSERVATION_MODIFIER", 10, 14]]], ["No reuse allowed without permission.Statistical analysis(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Statistical analysisThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprint Normality of the data assessed using Shapiro-Wilk test disclosed violation of the normality rules.", [["Statistical analysis", "TEST", 36, 56], ["Statistical analysis", "TEST", 191, 211], ["the data", "TEST", 366, 374], ["Shapiro-Wilk test", "TEST", 390, 407], ["med", "ANATOMY", 135, 138]]], ["As a result, we used Wilcoxon signed-rank test for repeated measure differences between baseline and Covid-19 levels of stress and depressive symptoms.", [["depressive symptoms", "DISEASE", 131, 150], ["rank test", "TEST", 37, 46], ["Covid", "TEST", 101, 106], ["stress", "PROBLEM", 120, 126], ["depressive symptoms", "PROBLEM", 131, 150]]], ["Between-group differences (based on sex, age, loneliness etc.) in gains of stress and depressive symptoms were examined Significance was evaluated at \u03b1=0.05 and all testing was 2-sided.Demographic characteristics of the Covid-19 population-based sampleThe Covid-19 population-based sample consisted of 715 participants, among whom 336 (47%) were men and 379 (53%) were women, with median age of 46 (range, 24-68; interquartile range, 36-56) ( Table 2 ).", [["depressive symptoms", "DISEASE", 86, 105], ["participants", "ORGANISM", 306, 318], ["men", "ORGANISM", 346, 349], ["women", "ORGANISM", 369, 374], ["participants", "SPECIES", 306, 318], ["men", "SPECIES", 346, 349], ["women", "SPECIES", 369, 374], ["stress and depressive symptoms", "PROBLEM", 75, 105], ["all testing", "TEST", 161, 172], ["the Covid", "TEST", 216, 225], ["The Covid", "TEST", 252, 261], ["interquartile range", "TEST", 413, 432]]], ["More specifically, stress levels increased significantly both in the ratio of individual stress categories, as well as the median of score of the PSS questionnaire (P<0.001) ( Table 2 and Figure 1A ).", [["stress levels", "TEST", 19, 32], ["the PSS questionnaire", "TEST", 142, 163], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["significantly", "OBSERVATION_MODIFIER", 43, 56]]], ["This significant increase in stress during Covid-19 was observed in both genders (both P<0.001), however, stress gain was significantly higher in females than in males (P=0.01) ( Table 2 ).", [["stress gain", "DISEASE", 106, 117], ["Covid", "TEST", 43, 48], ["stress gain", "PROBLEM", 106, 117], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["stress", "OBSERVATION_MODIFIER", 29, 35]]], ["Increase of stress during Covid-19 was significant for all age groups (all P<0.001) without between-group differences (P=0.89) ( Table 2 ).", [["Covid", "TEST", 26, 31]]], ["No reuse allowed without permission.Demographic characteristics of the Covid-19 population-based sample(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Demographic characteristics of the Covid-19 population-based sampleThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprintDepressive symptoms during Covid-19We next examined depressive symptoms before and during Covid-19.", [["Depressive symptoms", "DISEASE", 446, 465], ["depressive symptoms", "DISEASE", 498, 517], ["the Covid", "TEST", 67, 76], ["the Covid", "TEST", 269, 278], ["medRxiv", "TREATMENT", 430, 437], ["Depressive symptoms", "PROBLEM", 446, 465], ["Covid", "TEST", 473, 478], ["depressive symptoms", "PROBLEM", 498, 517], ["Covid", "TEST", 536, 541], ["med", "ANATOMY", 182, 185]]], ["Prevalence of depressive symptoms amounted to 49 cases (7%, 95% CI, 5.3%-9.2%) and 269 cases ( Figure 1C ).", [["depressive symptoms", "DISEASE", 14, 33], ["depressive symptoms", "PROBLEM", 14, 33], ["CI", "TEST", 64, 66]]], ["This rise in depressive symptoms was present in both sexes (both P<0.001) with females showing higher gain in severity of depressive symptoms than males (P=0.002) ( Table 2 ).", [["depressive symptoms", "DISEASE", 13, 32], ["depressive symptoms", "DISEASE", 122, 141], ["depressive symptoms", "PROBLEM", 13, 32], ["depressive symptoms", "PROBLEM", 122, 141], ["rise", "OBSERVATION_MODIFIER", 5, 9], ["depressive", "OBSERVATION_MODIFIER", 13, 23], ["symptoms", "OBSERVATION", 24, 32]]], ["Increase of severity of depressive symptoms during Covid-19 was significant for all age groups (median for all age groups 0; all P<0.001) without between-group differences (P=0.99) ( Table 2) .Risk factors for increased stress levels and depressive symptomsOne of the significant features of the quarantine was social isolation and distancing.", [["depressive symptoms", "DISEASE", 24, 43], ["depressive symptoms", "DISEASE", 238, 257], ["depressive symptoms", "PROBLEM", 24, 43], ["Covid", "TEST", 51, 56], ["Risk factors", "PROBLEM", 193, 205], ["increased stress levels", "PROBLEM", 210, 233], ["depressive symptoms", "PROBLEM", 238, 257], ["social isolation", "TREATMENT", 311, 327], ["significant", "OBSERVATION_MODIFIER", 268, 279], ["quarantine", "OBSERVATION", 296, 306]]], ["We therefore asked whether social isolation and distancing play a role in the gain of stress and depressive symptoms.", [["depressive symptoms", "DISEASE", 97, 116], ["social isolation", "TREATMENT", 27, 43], ["stress and depressive symptoms", "PROBLEM", 86, 116]]], ["The results indicated that those who spent quarantine alone or with others, showed significant increase of stress levels (both P<0.001) as well as depressive symptoms (both P<0.001) ( Table 3) .", [["depressive symptoms", "DISEASE", 147, 166], ["significant increase of stress levels", "PROBLEM", 83, 120], ["depressive symptoms", "PROBLEM", 147, 166], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["increase", "OBSERVATION_MODIFIER", 95, 103]]], ["We found no significant difference in gains of stress levels or depressive symptoms between those who spent the quarantine alone or with others (stress level: P=0.77; severity of depressive symptoms: P=0.33).Risk factors for increased stress levels and depressive symptomsWe next investigated whether feeling of loneliness contributes to increased stress levels and severity of depressive symptoms.", [["depressive", "DISEASE", 64, 74], ["depressive", "DISEASE", 179, 189], ["depressive symptoms", "DISEASE", 253, 272], ["loneliness", "DISEASE", 312, 322], ["depressive symptoms", "DISEASE", 378, 397], ["stress levels", "PROBLEM", 47, 60], ["depressive symptoms", "PROBLEM", 64, 83], ["depressive symptoms", "PROBLEM", 179, 198], ["Risk factors", "PROBLEM", 208, 220], ["increased stress levels", "PROBLEM", 225, 248], ["depressive symptoms", "PROBLEM", 253, 272], ["loneliness", "PROBLEM", 312, 322], ["increased stress levels", "PROBLEM", 338, 361], ["depressive symptoms", "PROBLEM", 378, 397], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34]]], ["We observed that participants reporting feelings of loneliness expressed significantly higher gains of stress level (P<0.001), and severity of depressive symptoms (P<0.001).", [["loneliness", "DISEASE", 52, 62], ["depressive symptoms", "DISEASE", 143, 162], ["participants", "SPECIES", 17, 29], ["stress level", "PROBLEM", 103, 115], ["depressive symptoms", "PROBLEM", 143, 162]]], ["Furthermore, within-group analysis showed that those who reported loneliness exhibited significantly greater increased of stress levels and depressive symptoms Figure 1B) .", [["loneliness", "DISEASE", 66, 76], ["depressive symptoms", "DISEASE", 140, 159], ["group analysis", "TEST", 20, 34], ["loneliness", "PROBLEM", 66, 76], ["stress levels", "PROBLEM", 122, 135], ["depressive symptoms", "PROBLEM", 140, 159]]], ["Last, we examined other possible risk factors that might be underlying psychological impact of Covid-19.", [["Covid", "TEST", 95, 100]]], ["To this end we assessed perception of Covid-19 disease and changes in daily life All rights reserved.", [["Covid-19 disease", "PROBLEM", 38, 54], ["changes in daily life", "TREATMENT", 59, 80]]], ["No reuse allowed without permission.Risk factors for increased stress levels and depressive symptoms(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Risk factors for increased stress levels and depressive symptomsThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprint functioning.", [["depressive symptoms", "DISEASE", 81, 100], ["depressive symptoms", "DISEASE", 280, 299], ["Risk factors", "PROBLEM", 36, 48], ["increased stress levels", "PROBLEM", 53, 76], ["depressive symptoms", "PROBLEM", 81, 100], ["Risk factors", "PROBLEM", 235, 247], ["increased stress levels", "PROBLEM", 252, 275], ["depressive symptoms", "PROBLEM", 280, 299], ["medRxiv preprint functioning", "TREATMENT", 424, 452], ["med", "ANATOMY", 179, 182]]], ["These results showed that the greater gains of stress levels and depressive symptoms were associated mainly with emotional response to the Covid-19 pandemic (Table 4 and Figure 1D ).", [["depressive", "DISEASE", 65, 75], ["stress levels", "PROBLEM", 47, 60], ["depressive symptoms", "PROBLEM", 65, 84], ["the Covid", "TEST", 135, 144], ["greater", "OBSERVATION_MODIFIER", 30, 37]]], ["In fact, the strongest association was present for increased negative emotions caused by Covid-19 (P<0.001).", [["increased negative emotions", "PROBLEM", 51, 78], ["Covid", "TEST", 89, 94]]], ["Furthermore, increased worry about Covid-19, overall perception of Covid-19 as a threatening disease and worsening of sleep length and quality were found to associate significantly with increased stress levels and severity of depressive symptoms (all P<0.001, see medians in Table 4 ).DiscussionsThe main goal of this study was to measure possible changes and magnitude of such changes in stress levels and severity of depressive symptoms before and during Covid-19 pandemic in a representative population-based sample.", [["depressive symptoms", "DISEASE", 226, 245], ["depressive symptoms", "DISEASE", 419, 438], ["Covid", "TEST", 35, 40], ["Covid", "TEST", 67, 72], ["a threatening disease", "PROBLEM", 79, 100], ["worsening of sleep length", "PROBLEM", 105, 130], ["increased stress levels", "PROBLEM", 186, 209], ["depressive symptoms", "PROBLEM", 226, 245], ["this study", "TEST", 313, 323], ["such changes in stress levels", "PROBLEM", 373, 402], ["depressive symptoms", "PROBLEM", 419, 438], ["Covid", "TEST", 457, 462], ["pandemic", "PROBLEM", 466, 474], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["worsening", "OBSERVATION_MODIFIER", 105, 114]]], ["Our results provide the first longitudinal measure of changes in several mental health indicators following Covid-19.", [["Covid", "TEST", 108, 113]]], ["They demonstrate that Covid-19 and related measures led to significant increase in stress levels and depressive symptoms.DiscussionsThis increase was consistent across all sex and age groups, revealing higher increase in females compared to males, and no differences among age groups.", [["depressive symptoms", "DISEASE", 101, 120], ["Covid", "TEST", 22, 27], ["significant increase in stress levels", "PROBLEM", 59, 96], ["depressive symptoms", "PROBLEM", 101, 120], ["higher increase in females", "PROBLEM", 202, 228], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["increase", "OBSERVATION_MODIFIER", 71, 79], ["stress levels", "OBSERVATION", 83, 96], ["higher", "OBSERVATION_MODIFIER", 202, 208], ["increase", "OBSERVATION_MODIFIER", 209, 217]]], ["We find this increase in stress levels and severity of depressive symptoms consistent with cross-sectional(3, 7) and longitudinal (28, 29) data from previous, although largely geographically limited, public health emergencies.", [["depressive symptoms", "DISEASE", 55, 74], ["stress levels", "PROBLEM", 25, 38], ["depressive symptoms", "PROBLEM", 55, 74], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["stress levels", "OBSERVATION", 25, 38]]], ["The results showed that stress levels increased less than severity of depressive symptoms.", [["depressive symptoms", "DISEASE", 70, 89], ["stress levels", "PROBLEM", 24, 37], ["depressive symptoms", "PROBLEM", 70, 89]]], ["This Except for the last possible explanation, which has already been documented as a likely cause of stress and depressive symptoms (30) (31) (32) , there is currently no data about other possible All rights reserved.", [["depressive symptoms", "DISEASE", 113, 132], ["stress and depressive symptoms", "PROBLEM", 102, 132], ["likely cause", "UNCERTAINTY", 86, 98]]], ["No reuse allowed without permission.Discussions(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionsThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprint explanations.", [["med", "ANATOMY", 126, 129]]], ["This strongly suggests that significant effort needs to be made to understand risk factors and other mechanisms underlying increase in stress levels and depressive symptoms in public health emergencies.DiscussionsThe second goal of this study was to identify possible risk factors and underlying mechanisms that play a role in the observed increase in stress levels and depressive symptoms during Covid-19 pandemic.", [["depressive symptoms", "DISEASE", 153, 172], ["depressive symptoms", "DISEASE", 370, 389], ["risk factors", "PROBLEM", 78, 90], ["stress levels", "PROBLEM", 135, 148], ["depressive symptoms", "PROBLEM", 153, 172], ["this study", "TEST", 232, 242], ["risk factors", "PROBLEM", 268, 280], ["stress levels", "PROBLEM", 352, 365], ["depressive symptoms", "PROBLEM", 370, 389], ["Covid", "TEST", 397, 402], ["pandemic", "PROBLEM", 406, 414], ["increase", "OBSERVATION_MODIFIER", 123, 131]]], ["The results, however, disclosed a strong role of emotional processing in the observed Covid-19-related increase in stress levels and depressive symptoms.DiscussionsThis manifested in significant effect of negative emotions associated with Covid-19 disease, increased worry regarding the disease, overall perception of Covid-19 as threatening, and extraordinary effect of loneliness.", [["depressive symptoms", "DISEASE", 133, 152], ["loneliness", "DISEASE", 371, 381], ["emotional processing", "PROBLEM", 49, 69], ["Covid", "TEST", 86, 91], ["stress levels", "PROBLEM", 115, 128], ["depressive symptoms", "PROBLEM", 133, 152], ["Covid-19 disease", "PROBLEM", 239, 255], ["the disease", "PROBLEM", 283, 294], ["Covid", "TEST", 318, 323], ["loneliness", "PROBLEM", 371, 381], ["increase", "OBSERVATION_MODIFIER", 103, 111]]], ["In fact, our data identify feeling of loneliness as the most important risk factor associated with the surge in stress and depressive symptoms.", [["loneliness", "DISEASE", 38, 48], ["depressive symptoms", "DISEASE", 123, 142], ["loneliness", "PROBLEM", 38, 48], ["depressive symptoms", "PROBLEM", 123, 142]]], ["These findings are consistent with previous studies, which established an intimate link between loneliness and psychological distress (33) (34) (35) .Conclusions and recommendationsThis study provides the first repeated-measure-based evidence of increase in stress levels and severity of depressive symptoms during Covid-19 compared to the levels prior to the pandemic. in person, via phone, or computer) and cognitive-behavioural techniques (36, 37) .", [["loneliness and psychological distress", "DISEASE", 96, 133], ["depressive symptoms", "DISEASE", 288, 307], ["person", "SPECIES", 373, 379], ["previous studies", "TEST", 35, 51], ["psychological distress", "PROBLEM", 111, 133], ["This study", "TEST", 181, 191], ["increase in stress levels", "PROBLEM", 246, 271], ["depressive symptoms", "PROBLEM", 288, 307], ["Covid", "TEST", 315, 320], ["the pandemic", "PROBLEM", 356, 368], ["consistent with", "UNCERTAINTY", 19, 34], ["increase", "OBSERVATION_MODIFIER", 246, 254], ["stress levels", "OBSERVATION", 258, 271]]], ["Culturally appropriate web-based prevention and intervention tools should also be developed (36, 38, 39) .Conclusions and recommendationsIn summary, diagnostics and therapeutics of mental disorders, which increase during pandemic will need to become timely and tailored to the specific measures imposed by the pandemics.", [["intervention tools", "TEST", 48, 66], ["diagnostics", "TEST", 149, 160], ["mental disorders", "PROBLEM", 181, 197]]], ["In addition, more intense and better organized approaches to mental distress of the general All rights reserved.", [["mental distress", "PROBLEM", 61, 76], ["more intense", "OBSERVATION_MODIFIER", 13, 25]]], ["No reuse allowed without permission.Conclusions and recommendations(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conclusions and recommendationsThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprint population will need to be integrated into global public health policies to protect mental health during future pandemics.Conclusions and recommendationsAll rights reserved.", [["medRxiv preprint population", "TREATMENT", 358, 385], ["med", "ANATOMY", 146, 149]]], ["No reuse allowed without permission.Conclusions and recommendations(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Conclusions and recommendationsThe copyright holder for this preprint this version posted July 29, 2020.Role of the Funder/Sponsor:The funders had no input in study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication.", [["data collection", "TEST", 375, 390], ["data analysis", "TEST", 392, 405], ["med", "ANATOMY", 146, 149]]], ["All authors had access to study data.", [["study data", "TEST", 26, 36]]], ["The corresponding author had final responsibility for the decision to submit for publication.Data sharing statement:The data used in this study are available on request immediately following the publication to anyone who submits the online request that will be approved by the St. Anne's University Hospital International Clinical Research Centre internal board.", [["this study", "TEST", 133, 143]]], ["The data will be provided for a limited and well-defined time via cloud service or email in csv format.", [["csv", "GENE_OR_GENE_PRODUCT", 92, 95]]], ["We thank the participants of the Kardiovize study for their participation on this Covid-19 add-on study.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and SilvieAll rights reserved.", [["participants", "SPECIES", 13, 25], ["the Kardiovize study", "TEST", 29, 49], ["this Covid", "TEST", 77, 87], ["study", "TEST", 98, 103], ["SilvieAll rights", "TREATMENT", 181, 197]]], ["No reuse allowed without permission.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and Silvie(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and SilvieThe copyright holder for this preprint this version posted July 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and SilvieThe copyright holder for this preprint this version posted July 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and SilvieThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprint IQR) . b University education includes higher vocational school, bachelor, master, and doctoral degrees. c Presence of feelings of loneliness was defined as score of 6 and more in UCLA 3-item Loneliness Scale.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and SilvieAll rights reserved.", [["loneliness", "DISEASE", 1194, 1204], ["loneliness", "PROBLEM", 1194, 1204], ["SilvieAll rights", "TREATMENT", 1349, 1365], ["med", "ANATOMY", 198, 201], ["med", "ANATOMY", 490, 493], ["med", "ANATOMY", 782, 785], ["loneliness", "OBSERVATION", 1194, 1204]]], ["No reuse allowed without permission.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and Silvie(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and SilvieThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprint All rights reserved.", [["medRxiv", "TREATMENT", 462, 469], ["med", "ANATOMY", 198, 201]]], ["No reuse allowed without permission.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and Silvie(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Additional Contributions: We are most thankful to Drs. Antonio Pompeiano and SilvieThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprintFigure 1.", [["medRxiv preprintFigure", "TREATMENT", 462, 484], ["med", "ANATOMY", 198, 201]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aa In A to C, the box plot lines correspond from the bottom of box to the top: 25th percentile, median percentile, and 75th percentile.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["the box plot lines", "TREATMENT", 197, 215]]], ["The dot represents mean, lines indicate changes in medians before and during Covid-19.", [["Covid", "TEST", 77, 82]]], ["Horizontal upper bars represent within-group differences with levels of significance, vertical side bar shows between-group difference of gain with levels of significance.Figure 1.", [["vertical side bar", "TEST", 86, 103], ["upper bars", "ANATOMY_MODIFIER", 11, 21]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aIn D, clustered heatmap shows Pearson's r effect sizes (with depicted levels of significance and horizontal clustering using the Wald method) based on Kruskal-Wallis/Dunn-Bonferroni test (with adjustment for multiple comparisons) of effect of individual secondary factors on gains of stress level and severity of depressive symptoms.Figure 1.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["depressive symptoms", "DISEASE", 497, 516], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["clustered heatmap", "TEST", 190, 207], ["Pearson's r effect sizes", "PROBLEM", 214, 238], ["the Wald method", "TEST", 309, 324], ["Bonferroni test", "TEST", 355, 370], ["individual secondary factors", "PROBLEM", 427, 455], ["stress level", "PROBLEM", 468, 480], ["depressive symptoms", "PROBLEM", 497, 516]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aAll rights reserved.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms a(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figure 1.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["med", "ANATOMY", 263, 266]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aThe copyright holder for this preprint this version posted July 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figure 1.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["med", "ANATOMY", 337, 340], ["med", "ANATOMY", 473, 476]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aThe copyright holder for this preprint this version posted July 29, 2020.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182]]], ["Have you been treated for arterial hypertension?Figure 1.", [["arterial", "ANATOMY", 26, 34], ["hypertension", "DISEASE", 35, 47], ["arterial", "MULTI-TISSUE_STRUCTURE", 26, 34], ["arterial hypertension", "PROBLEM", 26, 47], ["arterial", "ANATOMY", 26, 34], ["hypertension", "OBSERVATION", 35, 47]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aAll rights reserved.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms a(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figure 1.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["med", "ANATOMY", 263, 266]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aThe copyright holder for this preprint this version posted July 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figure 1.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["med", "ANATOMY", 337, 340]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprint eFigure 1: Flow-chart depicting selection of the participants in the Covid-19 research sample.Figure 1.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["participants", "SPECIES", 375, 387], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["the Covid", "TEST", 391, 400]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aAll rights reserved.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms a(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figure 1.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["med", "ANATOMY", 263, 266]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aThe copyright holder for this preprint this version posted July 29, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figure 1.", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["med", "ANATOMY", 337, 340]]], ["Prevalence of stress level and severity of depressive symptoms before and during Covid-19 and effect of secondary factors on gains of stress level and severity of depressive symptoms aThe copyright holder for this preprint this version posted July 29, 2020. . https://doi.org/10.1101/2020.07.28.20163113 doi: medRxiv preprint", [["depressive symptoms", "DISEASE", 43, 62], ["depressive symptoms", "DISEASE", 163, 182], ["stress level", "PROBLEM", 14, 26], ["depressive symptoms", "PROBLEM", 43, 62], ["Covid", "TEST", 81, 86], ["secondary factors", "PROBLEM", 104, 121], ["stress level", "PROBLEM", 134, 146], ["depressive symptoms", "PROBLEM", 163, 182], ["medRxiv", "TREATMENT", 309, 316]]]], "88f1e875045388fa81f4c2acb5ee569ce01ab2cf": [["TMEV is divided into two subgroups: GDVII and TO, based upon neurovirulence.", [["TMEV", "ORGANISM", 0, 4], ["TMEV", "SPECIES", 0, 4], ["TMEV", "PROBLEM", 0, 4], ["neurovirulence", "PROBLEM", 61, 75], ["neurovirulence", "OBSERVATION", 61, 75]]], ["In nature, TMEV transmission occurs by the fecaloral route, resulting in an unapparent infection of the gut (Lipton et al, 2006) ; however, on occasion, TMEV is able to infect the CNS (Theiler, 1934) .", [["gut", "ANATOMY", 104, 107], ["CNS", "ANATOMY", 180, 183], ["infection", "DISEASE", 87, 96], ["TMEV", "ORGANISM", 11, 15], ["gut", "ORGANISM_SUBDIVISION", 104, 107], ["TMEV", "ORGANISM", 153, 157], ["CNS", "ANATOMICAL_SYSTEM", 180, 183], ["Theiler", "ORGANISM", 185, 192], ["Theiler", "SPECIES", 185, 192], ["TMEV", "SPECIES", 11, 15], ["TMEV", "SPECIES", 153, 157], ["an unapparent infection of the gut", "PROBLEM", 73, 107], ["TMEV", "OBSERVATION", 11, 15], ["infection", "OBSERVATION", 87, 96], ["gut", "ANATOMY", 104, 107], ["CNS", "ANATOMY", 180, 183]]], ["We do not know how TMEV infects in the gut and spread into the CNS, although enteric TMEV infection can be a good model system to study how enteric virus disseminates into the CNS in humans.", [["gut", "ANATOMY", 39, 42], ["CNS", "ANATOMY", 63, 66], ["CNS", "ANATOMY", 176, 179], ["TMEV infection", "DISEASE", 85, 99], ["TMEV", "ORGANISM", 19, 23], ["gut", "ORGANISM_SUBDIVISION", 39, 42], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["TMEV", "ORGANISM", 85, 89], ["enteric virus", "ORGANISM", 140, 153], ["CNS", "ANATOMICAL_SYSTEM", 176, 179], ["humans", "ORGANISM", 183, 189], ["humans", "SPECIES", 183, 189], ["TMEV", "SPECIES", 19, 23], ["TMEV", "SPECIES", 85, 89], ["humans", "SPECIES", 183, 189], ["enteric TMEV infection", "PROBLEM", 77, 99], ["CNS", "ANATOMY", 63, 66], ["enteric", "ANATOMY", 77, 84], ["TMEV", "OBSERVATION", 85, 89], ["CNS", "ANATOMY", 176, 179]]]], "3aa35f88943fc8b448d654d8f1560a29f4e1b12a": [["Pneumonia is one of the most common infectious complications of stem cell transplantation (SCT).", [["stem cell", "ANATOMY", 64, 73], ["Pneumonia", "DISEASE", 0, 9], ["stem cell", "CELL", 64, 73], ["Pneumonia", "PROBLEM", 0, 9], ["stem cell transplantation", "TREATMENT", 64, 89], ["most common", "OBSERVATION_MODIFIER", 24, 35], ["infectious", "OBSERVATION_MODIFIER", 36, 46], ["stem cell transplantation", "OBSERVATION", 64, 89]]], ["During the past decade, infections due to respiratory viruses have increasingly been recognized as important causes of severe pneumonia in patients who have undergone SCT [1] [2] [3] .", [["infections", "DISEASE", 24, 34], ["respiratory viruses", "DISEASE", 42, 61], ["pneumonia", "DISEASE", 126, 135], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["infections", "PROBLEM", 24, 34], ["respiratory viruses", "PROBLEM", 42, 61], ["severe pneumonia", "PROBLEM", 119, 135], ["infections", "OBSERVATION", 24, 34], ["respiratory viruses", "OBSERVATION", 42, 61], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["pneumonia", "OBSERVATION", 126, 135]]], ["Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) have been especially associated with severe lower respiratory tract infections after SCT, causing high morbidity and mortality [4] [5] [6] [7] [8] .", [["lower respiratory tract", "ANATOMY", 108, 131], ["Respiratory syncytial virus (RSV) and parainfluenza virus", "DISEASE", 0, 57], ["lower respiratory tract infections", "DISEASE", 108, 142], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["parainfluenza virus", "ORGANISM", 38, 57], ["tract", "ORGANISM_SUBDIVISION", 126, 131], ["[4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 191, 210], ["Respiratory syncytial virus (RSV", "SPECIES", 0, 32], ["parainfluenza virus", "SPECIES", 38, 57], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["parainfluenza virus", "SPECIES", 38, 57], ["PIV", "SPECIES", 59, 62], ["Respiratory syncytial virus (RSV)", "PROBLEM", 0, 33], ["parainfluenza virus (PIV", "PROBLEM", 38, 62], ["severe lower respiratory tract infections", "PROBLEM", 101, 142], ["high morbidity", "PROBLEM", 162, 176], ["syncytial virus", "OBSERVATION", 12, 27], ["parainfluenza virus", "OBSERVATION", 38, 57], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["lower", "ANATOMY_MODIFIER", 108, 113], ["respiratory tract", "ANATOMY", 114, 131], ["infections", "OBSERVATION", 132, 142]]], ["However, the role of other respiratory viruses has not yet been sufficiently elucidated, and it is not clear whether respiratory viruses by themselves cause lower respiratory tract illnesses (LRTIs) or whether respiratory virus infection predisposes patients to additional infections [8] [9] [10] [11] .", [["lower respiratory tract", "ANATOMY", 157, 180], ["respiratory viruses", "DISEASE", 27, 46], ["respiratory viruses", "DISEASE", 117, 136], ["lower respiratory tract illnesses", "DISEASE", 157, 190], ["LRTIs", "DISEASE", 192, 197], ["respiratory virus infection", "DISEASE", 210, 237], ["infections", "DISEASE", 273, 283], ["lower", "ORGANISM", 157, 162], ["respiratory tract", "ORGANISM_SUBDIVISION", 163, 180], ["respiratory virus", "ORGANISM", 210, 227], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 250, 258], ["other respiratory viruses", "PROBLEM", 21, 46], ["respiratory viruses", "PROBLEM", 117, 136], ["lower respiratory tract illnesses", "PROBLEM", 157, 190], ["LRTIs", "PROBLEM", 192, 197], ["respiratory virus infection", "PROBLEM", 210, 237], ["additional infections", "PROBLEM", 262, 283], ["respiratory", "ANATOMY", 27, 38], ["viruses", "OBSERVATION", 39, 46], ["viruses", "OBSERVATION", 129, 136], ["respiratory tract", "ANATOMY", 163, 180], ["respiratory virus", "OBSERVATION", 210, 227]]], ["A sensitive method to assess the presence of respiratory viruses in the lower airways may be important to delineate the true incidence of respiratory virusassociated pneumonia.", [["lower airways", "ANATOMY", 72, 85], ["respiratory", "ANATOMY", 138, 149], ["respiratory viruses", "DISEASE", 45, 64], ["pneumonia", "DISEASE", 166, 175], ["lower airways", "ORGANISM_SUBDIVISION", 72, 85], ["respiratory viruses in the lower airways", "PROBLEM", 45, 85], ["respiratory virusassociated pneumonia", "PROBLEM", 138, 175], ["respiratory viruses", "OBSERVATION", 45, 64], ["lower", "ANATOMY_MODIFIER", 72, 77], ["airways", "ANATOMY", 78, 85], ["respiratory virusassociated", "OBSERVATION", 138, 165], ["pneumonia", "OBSERVATION", 166, 175]]], ["Moreover, a rapid and sensitive method for detection of respiratory viruses may be essential to guide implementation of therapy with current antiviral agents and to prevent or limit nosocomial spread of infection with respiratory viruses [12] [13] [14] .", [["respiratory viruses", "DISEASE", 56, 75], ["infection", "DISEASE", 203, 212], ["respiratory viruses", "DISEASE", 218, 237], ["respiratory viruses", "PROBLEM", 56, 75], ["therapy", "TREATMENT", 120, 127], ["current antiviral agents", "TREATMENT", 133, 157], ["nosocomial spread of infection", "PROBLEM", 182, 212], ["respiratory viruses", "PROBLEM", 218, 237], ["respiratory viruses", "OBSERVATION", 56, 75], ["infection", "OBSERVATION", 203, 212]]]], "f83eaa06108a3387433b69ff528e0ed986d77f5e": [["IntroductionOn December 2019, an outbreak of unexplained pneumonia occurred in Wuhan, China.", [["pneumonia", "DISEASE", 57, 66], ["unexplained pneumonia", "PROBLEM", 45, 66], ["unexplained", "OBSERVATION_MODIFIER", 45, 56], ["pneumonia", "OBSERVATION", 57, 66]]], ["On January 7, 2020, the causative pathogen was identified as a novel coronavirus, currently named SARS-CoV-2 [1] .", [["coronavirus", "DISEASE", 69, 80], ["coronavirus", "ORGANISM", 69, 80], ["SARS-CoV", "SPECIES", 98, 106], ["the causative pathogen", "PROBLEM", 20, 42], ["a novel coronavirus", "PROBLEM", 61, 80]]], ["The illness caused by this virus-COVID-19-spread swiftly around the globe, and on March 11, 2020, The World Health Organization (WHO) declared COVID-19 as a pandemic [2] .IntroductionIn most patients, the illness produce mild to moderate symptoms but approximately 15% progress to severe pneumonia, about 1% of patients experience progression that can quickly progress to profound hypoxemia and/or ARDS [3] .", [["illness", "DISEASE", 4, 11], ["illness", "DISEASE", 205, 212], ["pneumonia", "DISEASE", 288, 297], ["hypoxemia", "DISEASE", 381, 390], ["ARDS", "DISEASE", 398, 402], ["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 311, 319], ["The illness", "PROBLEM", 0, 11], ["this virus", "PROBLEM", 22, 32], ["COVID", "TEST", 33, 38], ["mild to moderate symptoms", "PROBLEM", 221, 246], ["severe pneumonia", "PROBLEM", 281, 297], ["profound hypoxemia", "PROBLEM", 372, 390], ["ARDS", "PROBLEM", 398, 402], ["globe", "ANATOMY", 68, 73], ["moderate", "OBSERVATION_MODIFIER", 229, 237], ["severe", "OBSERVATION_MODIFIER", 281, 287], ["pneumonia", "OBSERVATION", 288, 297], ["profound", "OBSERVATION_MODIFIER", 372, 380], ["hypoxemia", "OBSERVATION", 381, 390], ["ARDS", "OBSERVATION", 398, 402]]], ["As of June 25, 2020, more than 16.1 million cases of COVID-19 have been confirmed, with 645,752 deaths.", [["deaths", "DISEASE", 96, 102], ["COVID", "TEST", 53, 58]]], ["Currently, there are no specific approved treatment, nor a vaccine is available, and supportive care remains the cornerstone of management.IntroductionECMO is currently a widely accepted support measure for selected patients with life-threatening respiratory failure that does not respond to maximal support care with mechanical ventilation [4] .", [["respiratory", "ANATOMY", 247, 258], ["respiratory failure", "DISEASE", 247, 266], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["a vaccine", "TREATMENT", 57, 66], ["life-threatening respiratory failure", "PROBLEM", 230, 266], ["maximal support care", "TREATMENT", 292, 312], ["mechanical ventilation", "TREATMENT", 318, 340], ["no", "UNCERTAINTY", 21, 23], ["respiratory failure", "OBSERVATION", 247, 266]]], ["However, few centers have this technology available and some patients are too ill to be transferred under conventional transport (mechanical ventilation) to a facility that can provide it, meaning that they must be transferred on ECMO support to specialized centers [5] .", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["conventional transport (mechanical ventilation", "TREATMENT", 106, 152], ["ECMO support", "TREATMENT", 230, 242]]], ["Safety of healthcare workers is an important aspect of COVID-19 management.", [["COVID-19 management", "TREATMENT", 55, 74]]], ["Coronaviruses are believed to be transmitted from person to person via large respiratory droplets, either being inhaled or deposited on mucosal surfaces.", [["respiratory droplets", "ANATOMY", 77, 97], ["mucosal", "ANATOMY", 136, 143], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["mucosal surfaces", "TISSUE", 136, 152], ["person", "SPECIES", 50, 56], ["person", "SPECIES", 60, 66], ["Coronaviruses", "PROBLEM", 0, 13], ["large respiratory droplets", "PROBLEM", 71, 97], ["respiratory droplets", "OBSERVATION", 77, 97], ["mucosal surfaces", "ANATOMY", 136, 152]]], ["Other routes implicated in transmission of coronaviruses include contact with contaminated fomites and inhalation of aerosols produced during aerosol-generating procedures (AGPs).", [["coronaviruses", "DISEASE", 43, 56], ["coronaviruses", "ORGANISM", 43, 56], ["coronaviruses", "PROBLEM", 43, 56], ["inhalation of aerosols", "TREATMENT", 103, 125], ["aerosol-generating procedures", "TREATMENT", 142, 171]]], ["SARS-CoV-2 viral RNA has also been detected on rare occasions in blood specimens but there is no evidence of transmission through contact with blood [7] , for AGPs healthcare workers should use airborne-level personal protective equipment (PPE) [7] .IntroductionHere, we report the first interhospital extracorporeal membrane oxygenation transport of a COVID-19 patient in Chile.Case report51-year-old woman, with a history of hypothyroidism and mild asymptomatic asthma.", [["blood specimens", "ANATOMY", 65, 80], ["blood", "ANATOMY", 143, 148], ["interhospital extracorporeal membrane", "ANATOMY", 288, 325], ["SARS", "DISEASE", 0, 4], ["hypothyroidism", "DISEASE", 427, 441], ["asthma", "DISEASE", 464, 470], ["SARS-CoV-2", "ORGANISM", 0, 10], ["blood specimens", "ORGANISM_SUBSTANCE", 65, 80], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 302, 325], ["patient", "ORGANISM", 362, 369], ["woman", "ORGANISM", 402, 407], ["SARS-CoV-2 viral RNA", "RNA", 0, 20], ["patient", "SPECIES", 362, 369], ["woman", "SPECIES", 402, 407], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["2 viral RNA", "PROBLEM", 9, 20], ["blood specimens", "TEST", 65, 80], ["the first interhospital extracorporeal membrane oxygenation transport", "TREATMENT", 278, 347], ["a COVID", "TREATMENT", 351, 358], ["hypothyroidism", "PROBLEM", 427, 441], ["mild asymptomatic asthma", "PROBLEM", 446, 470], ["no evidence of", "UNCERTAINTY", 94, 108], ["hypothyroidism", "OBSERVATION", 427, 441], ["mild", "OBSERVATION_MODIFIER", 446, 450], ["asymptomatic", "OBSERVATION_MODIFIER", 451, 463], ["asthma", "OBSERVATION", 464, 470]]], ["Thirteen days prior to developing COVID-19 symptoms she arrived healthy from Dominican Republic, back to Punta Arenas, Chile.", [["developing COVID-19 symptoms", "PROBLEM", 23, 51]]], ["On March 29, 2020 she was admitted to the Regional Hospital after 2 days of progressive cough and malaise, associated with resting dyspnea.", [["cough", "DISEASE", 88, 93], ["resting dyspnea", "DISEASE", 123, 138], ["progressive cough", "PROBLEM", 76, 93], ["malaise", "PROBLEM", 98, 105], ["resting dyspnea", "PROBLEM", 123, 138], ["progressive", "OBSERVATION_MODIFIER", 76, 87], ["cough", "OBSERVATION", 88, 93], ["malaise", "OBSERVATION", 98, 105], ["dyspnea", "OBSERVATION", 131, 138]]], ["In the emergency department she had sinus tachycardia (heart rate (HR) 120 bpm), blood pressure 155/83 mmHg and polypnea [respiratory rate (RR) 40 bpm], 50% O 2 pulse oximetry on room air, with poor respiratory mechanics.", [["sinus", "ANATOMY", 36, 41], ["heart", "ANATOMY", 55, 60], ["blood", "ANATOMY", 81, 86], ["respiratory", "ANATOMY", 122, 133], ["respiratory", "ANATOMY", 199, 210], ["sinus tachycardia", "DISEASE", 36, 53], ["heart", "ORGAN", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["sinus tachycardia", "PROBLEM", 36, 53], ["heart rate", "TEST", 55, 65], ["HR", "TEST", 67, 69], ["blood pressure", "TEST", 81, 95], ["polypnea", "TEST", 112, 120], ["respiratory rate", "TEST", 122, 138], ["RR", "TEST", 140, 142], ["pulse oximetry", "TEST", 161, 175], ["poor respiratory mechanics", "PROBLEM", 194, 220], ["sinus", "ANATOMY", 36, 41], ["heart", "ANATOMY", 55, 60], ["respiratory mechanics", "OBSERVATION", 199, 220]]], ["Consequently, rapid sequence intubation was performed.", [["rapid sequence intubation", "TEST", 14, 39]]], ["Laboratory results showed 6.69 \u00d7 10 9 /L white blood cells, 1.17 \u00d7 10 9 /L lymphocyte, aspartate aminotransferase 19 U/L, alanine aminotransferase 12 U/L, lactate dehydrogenase 206 U/L; blood urea nitrogen 3.3 mmol/L, creatine kinase 76 mmol/L; procalcitonin 0.11 ng/mL, C-reactive protein 54.86 mg/L; blood gas analysis (ABGs): pH: 7.41, pO 2 91 mmHg, pCO 2 39 mmHg, fraction of inspired oxygen (F I O 2 ) 70%.", [["white blood cells", "ANATOMY", 41, 58], ["lymphocyte", "ANATOMY", 75, 85], ["blood", "ANATOMY", 186, 191], ["blood", "ANATOMY", 302, 307], ["aspartate", "CHEMICAL", 87, 96], ["alanine", "CHEMICAL", 122, 129], ["lactate", "CHEMICAL", 155, 162], ["blood urea nitrogen", "CHEMICAL", 186, 205], ["creatine", "CHEMICAL", 218, 226], ["oxygen", "CHEMICAL", 389, 395], ["aspartate", "CHEMICAL", 87, 96], ["alanine", "CHEMICAL", 122, 129], ["lactate", "CHEMICAL", 155, 162], ["urea", "CHEMICAL", 192, 196], ["nitrogen", "CHEMICAL", 197, 205], ["creatine", "CHEMICAL", 218, 226], ["oxygen", "CHEMICAL", 389, 395], ["blood cells", "CELL", 47, 58], ["lymphocyte", "CELL", 75, 85], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 87, 113], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 122, 146], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 155, 176], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["urea", "SIMPLE_CHEMICAL", 192, 196], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 218, 233], ["blood", "ORGANISM_SUBSTANCE", 302, 307], ["oxygen", "SIMPLE_CHEMICAL", 389, 395], ["aspartate aminotransferase", "PROTEIN", 87, 113], ["alanine aminotransferase", "PROTEIN", 122, 146], ["lactate dehydrogenase", "PROTEIN", 155, 176], ["creatine kinase", "PROTEIN", 218, 233], ["procalcitonin", "PROTEIN", 245, 258], ["C-reactive protein", "PROTEIN", 271, 289], ["white blood cells", "TEST", 41, 58], ["\u00d7", "TEST", 65, 66], ["lymphocyte", "TEST", 75, 85], ["aspartate aminotransferase", "TEST", 87, 113], ["U/L", "TEST", 117, 120], ["alanine aminotransferase", "TEST", 122, 146], ["U/L", "TEST", 150, 153], ["lactate dehydrogenase", "TEST", 155, 176], ["U", "TEST", 181, 182], ["blood urea nitrogen", "TEST", 186, 205], ["mmol", "TEST", 210, 214], ["creatine kinase", "TEST", 218, 233], ["mmol", "TEST", 237, 241], ["procalcitonin", "TEST", 245, 258], ["C-reactive protein", "TEST", 271, 289], ["blood gas analysis", "TEST", 302, 320], ["ABGs", "TEST", 322, 326], ["pH", "TEST", 329, 331], ["pO", "TEST", 339, 341], ["mmHg", "TEST", 347, 351], ["pCO", "TEST", 353, 356], ["mmHg", "TEST", 362, 366], ["fraction", "TEST", 368, 376], ["inspired oxygen (F I O", "TEST", 380, 402]]], ["Throat swabs of patients were harvested and tested positive for SARS-CoV-2 nucleic acid by the fluorescence quantitative RT-PCR.", [["Throat swabs", "ANATOMY", 0, 12], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 64, 87], ["Throat swabs", "ORGANISM_SUBSTANCE", 0, 12], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 64, 72], ["Throat swabs", "TEST", 0, 12], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["nucleic acid", "TEST", 75, 87], ["the fluorescence", "TEST", 91, 107], ["PCR", "TEST", 124, 127]]], ["PCR respiratory panel (FilmArray\u00ae), blood and deep airways cultures were negative for others infectious agents.Case reportChest CT scan showed severe bilateral alveolar condensation with isolated foci of normal parenchyma (Fig. 1) .", [["blood", "ANATOMY", 36, 41], ["airways cultures", "ANATOMY", 51, 67], ["alveolar", "ANATOMY", 160, 168], ["foci", "ANATOMY", 196, 200], ["parenchyma", "ANATOMY", 211, 221], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["airways cultures", "CELL", 51, 67], ["parenchyma", "TISSUE", 211, 221], ["PCR respiratory panel", "TEST", 0, 21], ["FilmArray\u00ae", "TEST", 23, 33], ["blood", "TEST", 36, 41], ["deep airways cultures", "TEST", 46, 67], ["Case reportChest CT scan", "TEST", 111, 135], ["severe bilateral alveolar condensation", "PROBLEM", 143, 181], ["blood", "ANATOMY", 36, 41], ["deep", "ANATOMY_MODIFIER", 46, 50], ["airways", "ANATOMY", 51, 58], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["bilateral", "ANATOMY_MODIFIER", 150, 159], ["alveolar", "ANATOMY", 160, 168], ["condensation", "OBSERVATION", 169, 181], ["isolated", "OBSERVATION_MODIFIER", 187, 195], ["foci", "OBSERVATION", 196, 200], ["normal", "OBSERVATION", 204, 210], ["parenchyma", "ANATOMY_MODIFIER", 211, 221]]], ["She was managed with on deep sedation (RASS-5), neuromuscular blockade, and recruitment maneuver; hemodynamics was maintained with low dose norepinephrine.", [["neuromuscular", "ANATOMY", 48, 61], ["neuromuscular blockade", "DISEASE", 48, 70], ["norepinephrine", "CHEMICAL", 140, 154], ["norepinephrine", "CHEMICAL", 140, 154], ["norepinephrine", "SIMPLE_CHEMICAL", 140, 154], ["deep sedation (RASS", "TREATMENT", 24, 43], ["neuromuscular blockade", "TREATMENT", 48, 70], ["recruitment maneuver", "TREATMENT", 76, 96], ["low dose norepinephrine", "TREATMENT", 131, 154]]], ["Ventilator settings were adjusted to volume-controlled ventilation 6 , pCO 2 63 mmHg.", [["Ventilator settings", "TREATMENT", 0, 19], ["volume-controlled ventilation", "TREATMENT", 37, 66], ["pCO", "TEST", 71, 74]]], ["As per protocole, oseltamivir, ceftriaxone, azithromycin and hydroxicloroquine were empirically started.", [["oseltamivir", "CHEMICAL", 18, 29], ["ceftriaxone", "CHEMICAL", 31, 42], ["azithromycin", "CHEMICAL", 44, 56], ["hydroxicloroquine", "CHEMICAL", 61, 78], ["oseltamivir", "CHEMICAL", 18, 29], ["ceftriaxone", "CHEMICAL", 31, 42], ["azithromycin", "CHEMICAL", 44, 56], ["hydroxicloroquine", "CHEMICAL", 61, 78], ["oseltamivir", "SIMPLE_CHEMICAL", 18, 29], ["ceftriaxone", "SIMPLE_CHEMICAL", 31, 42], ["azithromycin", "SIMPLE_CHEMICAL", 44, 56], ["hydroxicloroquine", "SIMPLE_CHEMICAL", 61, 78], ["oseltamivir", "TREATMENT", 18, 29], ["ceftriaxone", "TREATMENT", 31, 42], ["azithromycin", "TREATMENT", 44, 56], ["hydroxicloroquine", "TREATMENT", 61, 78]]], ["In the next hours PaO 2 /F I O 2 ratio deteriorated to 108 mmHg, without improvement after recruitment maneuvers nor the implementation of prone position.", [["O 2", "CHEMICAL", 29, 32], ["PaO 2 /F I O 2 ratio", "TEST", 18, 38], ["recruitment maneuvers", "TREATMENT", 91, 112]]], ["Guided per Chilean ARDS's recommendations, transfer to an ECMO unit was requested.", [["ARDS", "DISEASE", 19, 23]]], ["Due to patient condition and given distance from the nearest hospital with mobile ECMO capacity (3019 km), she was deemed to need airborne mobile ECMO.Case reportMobile ECMO team at Cl\u00ednica Las Condes was deployed, which is composed of a cardiac surgeon, an anesthetist, a perfusionist and an ICU nurse.", [["cardiac", "ANATOMY", 238, 245], ["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["patient condition", "PROBLEM", 7, 24], ["mobile ECMO capacity", "TREATMENT", 75, 95], ["airborne mobile ECMO", "TREATMENT", 130, 150]]], ["Since cardiac echoscopy showed no significant left ventricular disfunction, venovenous ECMO was installed.", [["cardiac", "ANATOMY", 6, 13], ["left ventricular", "ANATOMY", 46, 62], ["venovenous", "ANATOMY", 76, 86], ["cardiac", "ORGAN", 6, 13], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 46, 62], ["cardiac echoscopy", "TEST", 6, 23], ["significant left ventricular disfunction", "PROBLEM", 34, 74], ["venovenous ECMO", "TREATMENT", 76, 91], ["no", "UNCERTAINTY", 31, 33], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["left ventricular", "ANATOMY", 46, 62], ["disfunction", "OBSERVATION", 63, 74], ["venovenous ECMO", "OBSERVATION", 76, 91]]], ["Cannulation was guided by ultrasonography extraction from right femoral vein (29 Fr) and return to patient through right jugular vein (19 Fr).", [["right femoral vein", "ANATOMY", 58, 76], ["right jugular vein", "ANATOMY", 115, 133], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 64, 76], ["patient", "ORGANISM", 99, 106], ["right jugular vein", "MULTI-TISSUE_STRUCTURE", 115, 133], ["patient", "SPECIES", 99, 106], ["Cannulation", "TREATMENT", 0, 11], ["ultrasonography extraction", "TEST", 26, 52], ["right", "ANATOMY_MODIFIER", 58, 63], ["femoral vein", "ANATOMY", 64, 76], ["right", "ANATOMY_MODIFIER", 115, 120], ["jugular vein", "ANATOMY", 121, 133]]], ["Sweep gas flow 2 LPM; 3200 RPM, 3.4 ECMO flow, titrating parameters until 92% patient saturation.", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["Sweep gas flow", "TEST", 0, 14], ["ECMO flow", "TEST", 36, 45], ["titrating parameters", "TEST", 47, 67], ["patient saturation", "TEST", 78, 96]]], ["Rotaflow\u00ae centrifugal pump and PLS-i oxygenators (Maquet Cardiopulmonary Hirrlingen\u00ae, Germany) were used.", [["Rotaflow\u00ae centrifugal pump", "TREATMENT", 0, 26], ["PLS-i oxygenators", "TREATMENT", 31, 48], ["Cardiopulmonary Hirrlingen\u00ae, Germany)", "TREATMENT", 57, 94]]], ["No complications where reported during cannulation.", [["complications", "PROBLEM", 3, 16], ["cannulation", "TEST", 39, 50], ["complications", "OBSERVATION", 3, 16]]], ["Ventilatory settings where modified to pressure control 5 cm H 2 O, PEEP 5 cm H 2 O, RR 5 bpm, once leaving the hospital, the patient was left in inspiratory apnea at 8 cm H 2 O, and endotracheal tube was clamped to reduce the aerosolization risk.", [["endotracheal tube", "ANATOMY", 183, 200], ["apnea", "DISEASE", 158, 163], ["patient", "ORGANISM", 126, 133], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 183, 200], ["patient", "SPECIES", 126, 133], ["Ventilatory settings", "TREATMENT", 0, 20], ["pressure control", "TREATMENT", 39, 55], ["PEEP", "TEST", 68, 72], ["RR", "TEST", 85, 87], ["inspiratory apnea", "PROBLEM", 146, 163], ["endotracheal tube", "TREATMENT", 183, 200], ["the aerosolization risk", "PROBLEM", 223, 246], ["left", "ANATOMY_MODIFIER", 138, 142], ["inspiratory apnea", "OBSERVATION", 146, 163], ["endotracheal", "ANATOMY", 183, 195], ["tube", "OBSERVATION", 196, 200], ["aerosolization risk", "OBSERVATION", 227, 246]]], ["During all these maneuvers the whole team members used PPE according to air transmission; well-fitted N95 respirators, eye protection with visor or goggles, gloves, and long-sleeved impermeable protective gown.", [["eye", "ANATOMY", 119, 122], ["eye", "ORGAN", 119, 122], ["PPE", "TREATMENT", 55, 58], ["N95 respirators", "TREATMENT", 102, 117], ["eye protection", "TREATMENT", 119, 133], ["visor", "TREATMENT", 139, 144], ["gloves", "TREATMENT", 157, 163], ["eye", "ANATOMY", 119, 122]]], ["No complication occurred during the flight (Fig. 2) .", [["complication", "PROBLEM", 3, 15], ["complication", "OBSERVATION", 3, 15]]], ["To minimize the aerolization risk of SARS-CoV-2 through the gas-exit port of the membrane lung we kept a strict control for the detection of plasma leakage signs in the exhaust port of the oxygenator [8] .", [["membrane lung", "ANATOMY", 81, 94], ["plasma", "ANATOMY", 141, 147], ["SARS", "DISEASE", 37, 41], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["lung", "ORGAN", 90, 94], ["plasma", "ORGANISM_SUBSTANCE", 141, 147], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["a strict control", "TREATMENT", 103, 119], ["plasma leakage signs", "PROBLEM", 141, 161], ["the oxygenator", "TREATMENT", 185, 199], ["gas", "OBSERVATION", 60, 63], ["membrane lung", "ANATOMY", 81, 94]]], ["According to the Chilean Ministry of Health's guidelines for the transportation of COVID-19 patient, the crew (pilot and copilot) used droplets and contact sufficient PPE, embarked and disembarked at different time than healthcare personnel and patient; cabin was isolated from the rest of the aircraft and HEPA filters were used in ventilation circuits.", [["patient", "ORGANISM", 92, 99], ["patient", "ORGANISM", 245, 252], ["patient", "SPECIES", 92, 99], ["patient", "SPECIES", 245, 252], ["the crew (pilot and copilot)", "TREATMENT", 101, 129], ["droplets", "TREATMENT", 135, 143], ["HEPA filters", "TREATMENT", 307, 319], ["ventilation circuits", "TREATMENT", 333, 353], ["HEPA filters", "OBSERVATION", 307, 319], ["ventilation circuits", "OBSERVATION", 333, 353]]], ["After arrival, the cabin was disinfected with isopropyl alcohol and the rest of the aircraft with quaternary ammonium, and disinfection of the room-air was carried out by the filter using an ozone generating device.Case reportOn arrival at the referral center (Cl\u00ednica Las Condes, Santiago, Chile), endotracheal tube clamp was removed, and mechanical ventilation was set to pressure control, support pressure 10 cm H 2 O, RR 10 bpm, PEEP 10 cm H 2 O, F I O 2 30%.", [["endotracheal tube", "ANATOMY", 299, 316], ["isopropyl alcohol", "CHEMICAL", 46, 63], ["quaternary ammonium", "CHEMICAL", 98, 117], ["ozone", "CHEMICAL", 191, 196], ["isopropyl alcohol", "CHEMICAL", 46, 63], ["quaternary ammonium", "CHEMICAL", 98, 117], ["ozone", "CHEMICAL", 191, 196], ["isopropyl alcohol", "SIMPLE_CHEMICAL", 46, 63], ["ammonium", "SIMPLE_CHEMICAL", 109, 117], ["ozone", "SIMPLE_CHEMICAL", 191, 196], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 299, 316], ["isopropyl alcohol", "TREATMENT", 46, 63], ["quaternary ammonium", "TREATMENT", 98, 117], ["disinfection", "TREATMENT", 123, 135], ["an ozone generating device", "TREATMENT", 188, 214], ["endotracheal tube clamp", "TREATMENT", 299, 322], ["mechanical ventilation", "TREATMENT", 340, 362], ["support pressure", "TREATMENT", 392, 408], ["RR", "TEST", 422, 424], ["PEEP", "TEST", 433, 437], ["quaternary ammonium", "OBSERVATION", 98, 117], ["air", "OBSERVATION", 148, 151], ["endotracheal", "ANATOMY", 299, 311], ["tube clamp", "OBSERVATION", 312, 322], ["mechanical ventilation", "OBSERVATION", 340, 362]]], ["ABGs showed pH 7.38 pO 2 92.8 mmHg, pCO 2 32 mmHg.", [["ABGs", "SIMPLE_CHEMICAL", 0, 4], ["ABGs", "TEST", 0, 4], ["pH", "TEST", 12, 14], ["pO", "TEST", 20, 22], ["mmHg", "TEST", 30, 34], ["pCO", "TEST", 36, 39]]], ["Physical examination suggested deep vein thrombosis of right inferior limb, which was confirmed with echography, patient was transferred to the operating room, where vascular access was reconfigured to left axillar vein drainage, no significant recirculation nor other complication occurred.", [["deep vein", "ANATOMY", 31, 40], ["right inferior limb", "ANATOMY", 55, 74], ["vascular", "ANATOMY", 166, 174], ["left axillar vein", "ANATOMY", 202, 219], ["vein thrombosis", "DISEASE", 36, 51], ["deep vein", "MULTI-TISSUE_STRUCTURE", 31, 40], ["right", "ORGANISM_SUBDIVISION", 55, 60], ["inferior limb", "ORGANISM_SUBDIVISION", 61, 74], ["patient", "ORGANISM", 113, 120], ["vascular", "MULTI-TISSUE_STRUCTURE", 166, 174], ["axillar vein", "MULTI-TISSUE_STRUCTURE", 207, 219], ["patient", "SPECIES", 113, 120], ["Physical examination", "TEST", 0, 20], ["deep vein thrombosis of right inferior limb", "PROBLEM", 31, 74], ["echography", "TEST", 101, 111], ["left axillar vein drainage", "TREATMENT", 202, 228], ["significant recirculation", "PROBLEM", 233, 258], ["other complication", "PROBLEM", 263, 281], ["deep", "ANATOMY_MODIFIER", 31, 35], ["vein", "ANATOMY", 36, 40], ["thrombosis", "OBSERVATION", 41, 51], ["right", "ANATOMY_MODIFIER", 55, 60], ["inferior limb", "ANATOMY", 61, 74], ["vascular", "ANATOMY", 166, 174], ["left", "ANATOMY_MODIFIER", 202, 206], ["axillar vein", "ANATOMY", 207, 219], ["drainage", "OBSERVATION", 220, 228], ["no", "UNCERTAINTY", 230, 232], ["significant", "OBSERVATION_MODIFIER", 233, 244], ["recirculation", "OBSERVATION", 245, 258], ["complication", "OBSERVATION", 269, 281]]], ["Parameters where readjusted to 4 l pm RPM 3700 and FGF 3 lpm until ABGs normalized.Case reportProne position ventilation for 48 h and ultrafiltration through the circuit to reach negative water balance were implemented.", [["FGF 3 lpm", "GENE_OR_GENE_PRODUCT", 51, 60], ["FGF", "PROTEIN", 51, 54], ["FGF", "TEST", 51, 54], ["ABGs", "TEST", 67, 71], ["Case reportProne position ventilation", "TREATMENT", 83, 120], ["ultrafiltration", "TREATMENT", 134, 149], ["the circuit", "TREATMENT", 158, 169]]], ["Native lung function progressively improved and decannulation was undertaken on day 6th after cannulation.", [["lung", "ANATOMY", 7, 11], ["lung", "ORGAN", 7, 11], ["decannulation", "TREATMENT", 48, 61], ["cannulation", "TREATMENT", 94, 105], ["lung", "ANATOMY", 7, 11], ["function", "OBSERVATION", 12, 20], ["progressively", "OBSERVATION_MODIFIER", 21, 34], ["improved", "OBSERVATION_MODIFIER", 35, 43], ["decannulation", "OBSERVATION", 48, 61]]], ["An inferior vena cava filter was installed given the high thrombotic load.", [["inferior vena cava", "ANATOMY", 3, 21], ["thrombotic", "DISEASE", 58, 68], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 3, 21], ["An inferior vena cava filter", "TREATMENT", 0, 28], ["the high thrombotic load", "PROBLEM", 49, 73], ["inferior vena cava", "ANATOMY", 3, 21], ["filter", "OBSERVATION", 22, 28], ["high", "OBSERVATION_MODIFIER", 53, 57], ["thrombotic load", "OBSERVATION", 58, 73]]], ["Ten days of treatment with hydroxychloroquine were completed, azithromycin was stopped after 4 days due to QT prolongation.Case reportOn day 14th after admission, methicillin sensitive Staphylococcus aureus pneumonia was confirmed, cefazolin was started, and a second round of prone positioning was needed (48 h).", [["hydroxychloroquine", "CHEMICAL", 27, 45], ["azithromycin", "CHEMICAL", 62, 74], ["QT prolongation", "DISEASE", 107, 122], ["methicillin", "CHEMICAL", 163, 174], ["Staphylococcus aureus pneumonia", "DISEASE", 185, 216], ["cefazolin", "CHEMICAL", 232, 241], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["azithromycin", "CHEMICAL", 62, 74], ["methicillin", "CHEMICAL", 163, 174], ["cefazolin", "CHEMICAL", 232, 241], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 27, 45], ["azithromycin", "SIMPLE_CHEMICAL", 62, 74], ["methicillin sensitive Staphylococcus aureus", "ORGANISM", 163, 206], ["cefazolin", "SIMPLE_CHEMICAL", 232, 241], ["Staphylococcus aureus", "SPECIES", 185, 206], ["Staphylococcus aureus", "SPECIES", 185, 206], ["treatment", "TREATMENT", 12, 21], ["hydroxychloroquine", "TREATMENT", 27, 45], ["azithromycin", "TREATMENT", 62, 74], ["QT prolongation", "PROBLEM", 107, 122], ["methicillin sensitive Staphylococcus aureus pneumonia", "PROBLEM", 163, 216], ["cefazolin", "TREATMENT", 232, 241], ["prone positioning", "TREATMENT", 277, 294], ["Staphylococcus aureus", "OBSERVATION", 185, 206], ["pneumonia", "OBSERVATION", 207, 216]]], ["Considering prolonged invasive mechanical ventilation, tracheostomy was performed on day 24 after admission, with appropriate air-transmission PPE, without incidents.", [["prolonged invasive mechanical ventilation", "TREATMENT", 12, 53], ["tracheostomy", "TREATMENT", 55, 67], ["invasive", "OBSERVATION_MODIFIER", 22, 30], ["mechanical ventilation", "OBSERVATION", 31, 53], ["tracheostomy", "OBSERVATION", 55, 67]]], ["Given adequate clinical and laboratory response, neuromuscular blockade and deep sedation where progressively retired.", [["neuromuscular", "ANATOMY", 49, 62], ["neuromuscular blockade", "TREATMENT", 49, 71], ["deep sedation", "TREATMENT", 76, 89]]], ["A multimodal rehabilitation process was implemented, with a good response.", [["A multimodal rehabilitation process", "TREATMENT", 0, 35]]], ["Tracheostomy was removed, and the patient was discharged to home in a good general condition.DiscussionHere we report the first documented interhospital ECMO transport of a COVID-19 patient showing that it is feasible and safe if a mobile ECMO program is correctly implemented and the particularities of protective measures are properly taken.", [["patient", "ORGANISM", 34, 41], ["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 34, 41], ["patient", "SPECIES", 182, 189], ["Tracheostomy", "TREATMENT", 0, 12], ["a COVID", "TEST", 171, 178], ["a mobile ECMO program", "TREATMENT", 230, 251], ["protective measures", "TREATMENT", 304, 323]]], ["ECMO was studied for ARDS treatment in patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a similar coronavirus disease that emerged in 2012, showing a significant decrease of in-hospital mortality in patients supported by ECMO compared to those managed with conventional therapy [9] .", [["ARDS", "DISEASE", 21, 25], ["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 53, 97], ["coronavirus disease", "DISEASE", 120, 139], ["patients", "ORGANISM", 39, 47], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 53, 97], ["MERS-CoV", "ORGANISM", 99, 107], ["coronavirus", "ORGANISM", 120, 131], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 221, 229], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 53, 107], ["ECMO", "TREATMENT", 0, 4], ["ARDS treatment", "TREATMENT", 21, 35], ["Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 53, 97], ["a similar coronavirus disease", "PROBLEM", 110, 139], ["ECMO", "TREATMENT", 243, 247], ["conventional therapy", "TREATMENT", 279, 299], ["Respiratory Syndrome", "OBSERVATION", 65, 85], ["coronavirus disease", "OBSERVATION", 120, 139], ["significant", "OBSERVATION_MODIFIER", 172, 183], ["decrease", "OBSERVATION_MODIFIER", 184, 192]]], ["At this time there is little worldwide reported experience regarding ECMO support on COVID-19 patients [10] [11] [12] , although the WHO's guidance document includes a statement to \"consider referral patients with refractory hypoxemia despite lung-protective ventilation in settings with access to expertise in ECMO [13] .", [["lung", "ANATOMY", 243, 247], ["hypoxemia", "DISEASE", 225, 234], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 200, 208], ["lung", "ORGAN", 243, 247], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 200, 208], ["ECMO support", "TREATMENT", 69, 81], ["COVID", "TEST", 85, 90], ["refractory hypoxemia", "PROBLEM", 214, 234], ["lung-protective ventilation", "TREATMENT", 243, 270], ["ECMO", "TREATMENT", 311, 315], ["lung", "ANATOMY", 243, 247]]], ["Considering that, if ECMO expertise is available, it should be considered into ARDS managing algorithms, including ARDS secondary to viral pneumonia.DiscussionThe Extracorporeal Life Support Organization (ELSO) reports at July 25, 2020, 1972 confirmed COVID-19 cases have been supported with ECMO, and 55% of discharged patients are alive (753 out 1365).", [["ARDS", "DISEASE", 79, 83], ["ARDS", "DISEASE", 115, 119], ["viral pneumonia", "DISEASE", 133, 148], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 320, 328], ["ARDS managing algorithms", "PROBLEM", 79, 103], ["ARDS", "PROBLEM", 115, 119], ["viral pneumonia", "PROBLEM", 133, 148], ["ECMO", "TREATMENT", 292, 296], ["ARDS", "OBSERVATION", 115, 119], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["pneumonia", "OBSERVATION", 139, 148]]], ["As treatment for severe respiratory failure with ECMO requires specialized knowledge and training, the number of patients annually supported with ECMO is positively associated with the survival rate [5] .", [["respiratory", "ANATOMY", 24, 35], ["respiratory failure", "DISEASE", 24, 43], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["treatment", "TREATMENT", 3, 12], ["severe respiratory failure", "PROBLEM", 17, 43], ["ECMO", "TREATMENT", 49, 53], ["ECMO", "TREATMENT", 146, 150], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["respiratory", "ANATOMY", 24, 35], ["failure", "OBSERVATION", 36, 43]]], ["It is also known that hospitalization at a center, where health care professionals are well-trained on respiratory care results in improved outcomes [14] .", [["respiratory care", "TREATMENT", 103, 119]]], ["Therefore, it is recommended that those patients who meet the criteria to be connected to ECMO should be transferred to centers with high experience in this technique [12] .DiscussionHowever, few centers have this technology available in situ and some patients are too ill to be transferred under conventional transport (mechanical ventilation) to a facility that can provide it, meaning that they must be transferred on ECMO support to specialized centers [5] .DiscussionOn March 3 2020, the first COVID-19 case was reported in Chile and as on July 25 the Ministry of Health has reported 343,592 COVID-19 confirmed cases nationwide, 1% of them are considered serious or critical, and by the time of this publication, 80 patients have been supported with ECMO.DiscussionChile is an upper middle income country with a population of 19.4 million people.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 252, 260], ["patients", "ORGANISM", 721, 729], ["people", "ORGANISM", 844, 850], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 252, 260], ["patients", "SPECIES", 721, 729], ["people", "SPECIES", 844, 850], ["ECMO", "TREATMENT", 90, 94], ["this technology", "TREATMENT", 209, 224], ["mechanical ventilation", "TREATMENT", 321, 343], ["ECMO support", "TREATMENT", 421, 433], ["COVID", "TEST", 597, 602], ["ECMO", "TREATMENT", 755, 759], ["upper", "ANATOMY_MODIFIER", 782, 787], ["middle", "ANATOMY_MODIFIER", 788, 794]]], ["Fifteen clinical centers can provide ECMO support distributed in only 6 cities; therefore, patients from remote regions requiring advanced support with ECMO, need to be transferred to these centers.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["ECMO support", "TREATMENT", 37, 49], ["advanced support", "TREATMENT", 130, 146], ["ECMO", "TREATMENT", 152, 156]]], ["In Chile, there is a central coordination system that analyzes requests for ECMO support from all hospitals in the country.DiscussionWhen the need for ECMO is confirmed, each patient is referred to one of the 29 available beds in ECMO centers throughout the country [15] .", [["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 175, 182], ["ECMO support", "TREATMENT", 76, 88], ["ECMO", "TREATMENT", 151, 155]]], ["Currently only one center in Chile transport ECMO patients on a regular basis, although they have been done sporadically by others.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Figure 3 shows map providing information on the location of ECMO centers in the country.", [["ECMO centers", "TREATMENT", 60, 72]]], ["Here we report the first interhospital ECMO transport of a COVID-19 patient in our country and, to our knowledge, the first case described.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]], ["The patient was too ill to undergo conventional transport, so had to be moved under ECMO support to Santiago.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["ECMO support", "TREATMENT", 84, 96]]], ["Patient was cannulated by ECMO mobile team at the referral center in Punta Arenas and successfully transferred to Cl\u00ednica las Condes, in Santiago by airplane without any complication during transport.DiscussionAn important aspect to pay attention in patients with COVID-19 is the safety of health care workers.", [["patients", "ORGANISM", 250, 258], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 250, 258], ["any complication", "PROBLEM", 166, 182]]], ["In this case, all team members used personal protective equipment according to the procedure with generation of aerosols and the crew members used PPE to droplets and contact transmission.", [["personal protective equipment", "TREATMENT", 36, 65], ["the procedure", "TREATMENT", 79, 92], ["generation of aerosols", "TREATMENT", 98, 120]]], ["To minimize risk of air circuit disconnection and aerosolization during flight we decided to clamp endotracheal tube.", [["endotracheal tube", "ANATOMY", 99, 116], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 99, 116], ["air circuit disconnection", "TREATMENT", 20, 45], ["aerosolization", "TREATMENT", 50, 64], ["clamp endotracheal tube", "TREATMENT", 93, 116], ["air circuit", "OBSERVATION", 20, 31], ["endotracheal tube", "OBSERVATION", 99, 116]]], ["Other ECMO teams use a strong tape to secure the connection between endotracheal tube and mechanical ventilator, but we prefer endotracheal tube clamping to avoid the risk of endotracheal tube displacement/damage at time of taping remove minimizing the risk of tube replacement need in a COVID19 patient.DiscussionAll heath workers in Cl\u00ednica las Condes had receive previous training in the use of PPE and the air transport company (AeroTac) has also established protocols for the transportation of COVID-19 patient.", [["endotracheal tube", "ANATOMY", 68, 85], ["endotracheal tube", "ANATOMY", 127, 144], ["endotracheal tube", "ANATOMY", 175, 192], ["tube", "ANATOMY", 261, 265], ["endotracheal tube", "TISSUE", 68, 85], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 127, 144], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 175, 192], ["tube", "TISSUE", 261, 265], ["patient", "ORGANISM", 296, 303], ["patient", "ORGANISM", 508, 515], ["patient", "SPECIES", 296, 303], ["patient", "SPECIES", 508, 515], ["a strong tape", "TREATMENT", 21, 34], ["endotracheal tube", "TREATMENT", 68, 85], ["mechanical ventilator", "TREATMENT", 90, 111], ["endotracheal tube clamping", "TREATMENT", 127, 153], ["endotracheal tube displacement", "PROBLEM", 175, 205], ["damage", "PROBLEM", 206, 212], ["taping", "TREATMENT", 224, 230], ["tube replacement", "TREATMENT", 261, 277], ["previous training", "TREATMENT", 366, 383], ["PPE", "TREATMENT", 398, 401], ["endotracheal tube", "OBSERVATION", 68, 85], ["mechanical ventilator", "OBSERVATION", 90, 111], ["tube clamping", "OBSERVATION", 140, 153], ["endotracheal", "OBSERVATION", 175, 187], ["tube displacement", "OBSERVATION", 188, 205], ["tube replacement", "OBSERVATION", 261, 277]]], ["After 21 days, none of the members participating in the cannulation procedure nor in the transport was infected with SARS-Cov-2.DiscussionThe experience of the rescue team can also be an important factor in the final outcomes.", [["SARS", "DISEASE", 117, 121], ["the cannulation procedure", "TREATMENT", 52, 77]]], ["Cl\u00ednica las Condes began the mobile ECMO program in March 2007 and until now, more than 120 patients have been transported to specialized centers.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100]]], ["Although there is still little evidence regarding the utility of ECMO in ARDS by COVID-19, the utility in other pathologies that occur with severe ARDS has been demonstrated; waiting to gain more knowledge about this disease, patients undergoing ECMO should be managed in experienced centers.", [["ARDS", "DISEASE", 73, 77], ["ARDS", "DISEASE", 147, 151], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["ECMO", "TREATMENT", 65, 69], ["ARDS", "PROBLEM", 73, 77], ["COVID", "TEST", 81, 86], ["other pathologies", "PROBLEM", 106, 123], ["severe ARDS", "PROBLEM", 140, 151], ["this disease", "PROBLEM", 212, 224], ["ECMO", "TREATMENT", 246, 250], ["ECMO", "OBSERVATION", 65, 69], ["ARDS", "OBSERVATION", 73, 77], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["ARDS", "OBSERVATION", 147, 151]]], ["The transfer of these patients by experienced and consolidated ECMO transport teams, in addition to protocols of infection prevention and control measures could significantly influence the outcome of both the patient's disease and the safety of the health workers.DiscussionFunding None.Compliance with ethical standardsConflict of interest Felipe Salech is currently receiving a Grant from \"FONDECYT\" (Chilean government research Grant) #11190882.", [["infection", "DISEASE", 113, 122], ["patients", "ORGANISM", 22, 30], ["patient", "ORGANISM", 209, 216], ["patients", "SPECIES", 22, 30], ["patient", "SPECIES", 209, 216], ["infection prevention", "TREATMENT", 113, 133], ["control measures", "TREATMENT", 138, 154], ["the patient's disease", "PROBLEM", 205, 226], ["ethical standards", "TREATMENT", 303, 320], ["infection", "OBSERVATION", 113, 122]]], ["The remaining authors have disclosed that they do not have any conflicts of interest.Compliance with ethical standardsEthics and institutional review board A document review approval of the above case report was performed by the Review Board, as well as by the Ethics Committee of Cl\u00ednica las Condes.", [["ethical standards", "TREATMENT", 101, 118]]], ["After a detailed descriptions of the case report, a relative of the patient signed a written informed consent for publication of results.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]]], "47542d18ce5091453d9eca76506a20a78d78f292": [["synthesis of lactate intracellularly is crucial for T cells to have an increased glycolytic flux38.146Peripheral blood mononuclear cells (PBMCs) can be analyzed to measure the health status 147 of an individual and can serve as a health biomarkers42.", [["T cells", "ANATOMY", 52, 59], ["Peripheral blood mononuclear cells", "ANATOMY", 102, 136], ["PBMCs", "ANATOMY", 138, 143], ["lactate", "CHEMICAL", 13, 20], ["lactate", "CHEMICAL", 13, 20], ["lactate", "SIMPLE_CHEMICAL", 13, 20], ["T cells", "CELL", 52, 59], ["Peripheral blood mononuclear cells", "CELL", 102, 136], ["PBMCs", "CELL", 138, 143], ["T cells", "CELL_TYPE", 52, 59], ["Peripheral blood mononuclear cells", "CELL_TYPE", 102, 136], ["PBMCs", "CELL_TYPE", 138, 143], ["synthesis of lactate intracellularly", "TEST", 0, 36], ["T cells", "PROBLEM", 52, 59], ["an increased glycolytic", "PROBLEM", 68, 91], ["Peripheral blood mononuclear cells", "TREATMENT", 102, 136], ["PBMCs", "TEST", 138, 143], ["a health biomarkers", "TEST", 228, 247], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["glycolytic flux38.146", "OBSERVATION", 81, 102], ["mononuclear cells", "OBSERVATION", 119, 136]]], ["Therefore, the metabolic status of 148 lymphocytes could help to predict disease severity or to select the optimal therapeutic 149 intervention to boost the immune function during infection.", [["lymphocytes", "ANATOMY", 39, 50], ["infection", "DISEASE", 180, 189], ["lymphocytes", "CELL", 39, 50], ["148 lymphocytes", "CELL_TYPE", 35, 50], ["lymphocytes", "PROBLEM", 39, 50], ["disease severity", "PROBLEM", 73, 89], ["infection", "PROBLEM", 180, 189], ["infection", "OBSERVATION", 180, 189]]], ["Generally, most of the metabolism- to the hospital requiring medical care, however, they did not need ventilation or O2 supply.170Recovered patients were included based on a positive SARS-CoV-2 antibody testing.", [["O2", "CHEMICAL", 117, 119], ["O2", "CHEMICAL", 117, 119], ["O2", "SIMPLE_CHEMICAL", 117, 119], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["medical care", "TREATMENT", 61, 73], ["ventilation", "TREATMENT", 102, 113], ["O2 supply", "TREATMENT", 117, 126], ["a positive SARS", "PROBLEM", 172, 187], ["CoV", "TEST", 188, 191], ["antibody testing", "TEST", 194, 210]]], ["Study 171 participant characteristics are described in Table 2 .173Immunophenotyping of COVID-19 mild, moderate and convalescent175To compare the number of lymphocytes and monocytes amongst the four study groups,176PBMCs were stained and analysed by flow cytometry.", [["lymphocytes", "ANATOMY", 156, 167], ["monocytes", "ANATOMY", 172, 181], ["176PBMCs", "ANATOMY", 212, 220], ["lymphocytes", "CELL", 156, 167], ["monocytes", "CELL", 172, 181], ["176PBMCs", "CELL", 212, 220], ["lymphocytes", "CELL_TYPE", 156, 167], ["monocytes", "CELL_TYPE", 172, 181], ["Immunophenotyping", "TEST", 67, 84], ["COVID", "TEST", 88, 93], ["mild, moderate and convalescent", "PROBLEM", 97, 128], ["lymphocytes", "TEST", 156, 167], ["monocytes", "TEST", 172, 181], ["the four study groups", "TEST", 190, 211], ["flow cytometry", "TEST", 250, 264], ["mild", "OBSERVATION_MODIFIER", 97, 101], ["moderate", "OBSERVATION_MODIFIER", 103, 111], ["flow cytometry", "OBSERVATION", 250, 264]]], ["Both, lymphocytes (p=0.005) and 177 monocytes (p=0.04), were significantly decreased in moderate COVID-19 patients compared 178 with HC (Suppl.", [["lymphocytes", "ANATOMY", 6, 17], ["monocytes", "ANATOMY", 36, 45], ["lymphocytes", "CELL", 6, 17], ["monocytes", "CELL", 36, 45], ["patients", "ORGANISM", 106, 114], ["lymphocytes", "CELL_TYPE", 6, 17], ["177 monocytes", "CELL_TYPE", 32, 45], ["patients", "SPECIES", 106, 114], ["lymphocytes", "TEST", 6, 17], ["monocytes", "TEST", 36, 45], ["moderate COVID", "TEST", 88, 102], ["HC", "TEST", 133, 135], ["lymphocytes", "ANATOMY", 6, 17], ["decreased", "OBSERVATION_MODIFIER", 75, 84], ["moderate", "OBSERVATION_MODIFIER", 88, 96]]], ["However, mild and convalescent patients also had a reduced, but 179 not significantly reduced, count of lymphocytes/monocytes compared to HC.183Monocytes were further classified into classical, non-classical and intermediate based on 184 expression of CD14 and/or CD16 and we used the same gating strategies as described 185 earlier44 (Suppl.", [["lymphocytes", "ANATOMY", 104, 115], ["monocytes", "ANATOMY", 116, 125], ["Monocytes", "ANATOMY", 144, 153], ["patients", "ORGANISM", 31, 39], ["lymphocytes", "CELL", 104, 115], ["monocytes", "CELL", 116, 125], ["HC", "CELL", 138, 140], ["Monocytes", "CELL", 144, 153], ["CD14", "GENE_OR_GENE_PRODUCT", 252, 256], ["CD16", "GENE_OR_GENE_PRODUCT", 264, 268], ["lymphocytes", "CELL_TYPE", 104, 115], ["monocytes", "CELL_TYPE", 116, 125], ["HC", "CELL_TYPE", 138, 140], ["Monocytes", "CELL_TYPE", 144, 153], ["CD14", "PROTEIN", 252, 256], ["CD16", "PROTEIN", 264, 268], ["patients", "SPECIES", 31, 39], ["lymphocytes", "TEST", 104, 115], ["monocytes", "TEST", 116, 125], ["HC", "TEST", 138, 140], ["Monocytes", "TEST", 144, 153], ["CD14", "TEST", 252, 256], ["CD16", "TEST", 264, 268], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["convalescent", "OBSERVATION_MODIFIER", 18, 30], ["reduced", "OBSERVATION_MODIFIER", 51, 58], ["reduced", "OBSERVATION_MODIFIER", 86, 93]]], ["We found that CD16++CD14+ patrolling (non-classical) monocytes 186 were significantly increased (p=0.0008) in numbers in moderate patients compared to HC, 187 whereas this number is decreased again significantly compared with convalescent patients 188 (p=0.01) (Fig. 1a) .", [["CD16++CD14+ patrolling (non-classical) monocytes", "ANATOMY", 14, 62], ["CD16", "GENE_OR_GENE_PRODUCT", 14, 18], ["CD14", "GENE_OR_GENE_PRODUCT", 20, 24], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 239, 247], ["CD16", "PROTEIN", 14, 18], ["CD14", "PROTEIN", 20, 24], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 239, 247], ["CD16", "TEST", 14, 18], ["CD14", "TEST", 20, 24], ["monocytes", "TEST", 53, 62], ["HC", "TEST", 151, 153], ["significantly", "OBSERVATION_MODIFIER", 72, 85], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["moderate", "OBSERVATION_MODIFIER", 121, 129], ["decreased", "OBSERVATION_MODIFIER", 182, 191]]], ["The percentage of CD16++CD14+ monocytes was also significantly 189 increased (p=0.006) in mild patients (outpatients) compared with moderate patients (Fig. 1a 190 Panel I).", [["CD16++CD14+ monocytes", "ANATOMY", 18, 39], ["CD16", "GENE_OR_GENE_PRODUCT", 18, 22], ["CD14", "GENE_OR_GENE_PRODUCT", 24, 28], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 141, 149], ["CD16", "PROTEIN", 18, 22], ["CD14", "PROTEIN", 24, 28], ["monocytes", "CELL_TYPE", 30, 39], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 141, 149], ["The percentage of CD16", "TEST", 0, 22], ["CD14", "TEST", 24, 28], ["monocytes", "TEST", 30, 39], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["mild", "OBSERVATION_MODIFIER", 90, 94]]], ["Interestingly, CD16++CD14++ pro-inflammatory monocytes (intermediate) were again 191 of CD14++CD16-phagocytic monocytes (classical) in moderate compared with mild convalescent and HC (p<0.0001; HC vs mild or moderate) patients (Fig. 1b) .201Both T and B cells are indispensable for the immune response against viral infections such as 202 SARS-CoV-2.", [["CD16++CD14++ pro-inflammatory monocytes", "ANATOMY", 15, 54], ["CD14++CD16-phagocytic monocytes", "ANATOMY", 88, 119], ["T", "ANATOMY", 246, 247], ["B cells", "ANATOMY", 252, 259], ["viral infections", "DISEASE", 310, 326], ["CD16", "GENE_OR_GENE_PRODUCT", 15, 19], ["CD14", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD14", "GENE_OR_GENE_PRODUCT", 88, 92], ["CD16", "GENE_OR_GENE_PRODUCT", 94, 98], ["patients", "ORGANISM", 218, 226], ["T", "CELL", 246, 247], ["B cells", "CELL", 252, 259], ["CD16", "PROTEIN", 15, 19], ["CD14", "PROTEIN", 21, 25], ["pro-inflammatory monocytes", "CELL_TYPE", 28, 54], ["CD14", "PROTEIN", 88, 92], ["CD16", "PROTEIN", 94, 98], ["phagocytic monocytes", "CELL_TYPE", 99, 119], ["T and B cells", "CELL_TYPE", 246, 259], ["patients", "SPECIES", 218, 226], ["CD16", "TEST", 15, 19], ["CD14", "TEST", 21, 25], ["pro-inflammatory monocytes", "TEST", 28, 54], ["CD14", "TEST", 88, 92], ["CD16", "TEST", 94, 98], ["phagocytic monocytes", "TEST", 99, 119], ["mild convalescent", "PROBLEM", 158, 175], ["HC", "TEST", 180, 182], ["HC", "TEST", 194, 196], ["mild or moderate) patients", "PROBLEM", 200, 226], ["Fig.", "TEST", 228, 232], ["viral infections", "PROBLEM", 310, 326], ["CoV", "TEST", 344, 347], ["pro-inflammatory monocytes", "OBSERVATION", 28, 54], ["phagocytic monocytes", "OBSERVATION", 99, 119], ["moderate", "OBSERVATION_MODIFIER", 135, 143], ["mild", "OBSERVATION_MODIFIER", 158, 162], ["moderate", "OBSERVATION_MODIFIER", 208, 216]]], ["Firstly, we compared the number of B cells amongst the study groups, which 203 give rise to virus-specific antibodies (see gating strategy in Suppl.", [["B cells", "ANATOMY", 35, 42], ["B cells", "CELL", 35, 42], ["B cells", "CELL_TYPE", 35, 42], ["virus-specific antibodies", "PROTEIN", 92, 117], ["Suppl", "PROTEIN", 142, 147], ["the study groups", "TEST", 51, 67], ["virus", "TEST", 92, 97]]], ["The CD19+CD3-204 cells (B cells) were significantly increased in mild (p=0.008; 1.7x times) and moderate 205 (p=0.0008; 1.9x times) patients compared with HC (Fig. 2a)211CD3+ cells were analysed for the CD4+ and CD8+ T cell compartment.", [["CD19+CD3-204 cells", "ANATOMY", 4, 22], ["B cells", "ANATOMY", 24, 31], ["Fig. 2a)211CD3+ cells", "ANATOMY", 159, 180], ["CD4+", "ANATOMY", 203, 207], ["T cell compartment", "ANATOMY", 217, 235], ["CD19", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD3", "GENE_OR_GENE_PRODUCT", 9, 12], ["B cells", "CELL", 24, 31], ["patients", "ORGANISM", 132, 140], ["CD4", "GENE_OR_GENE_PRODUCT", 203, 206], ["CD8", "GENE_OR_GENE_PRODUCT", 212, 215], ["T cell", "CELL", 217, 223], ["CD19", "PROTEIN", 4, 8], ["CD3", "PROTEIN", 9, 12], ["204 cells", "CELL_LINE", 13, 22], ["B cells", "CELL_TYPE", 24, 31], ["CD4", "PROTEIN", 203, 206], ["CD8", "PROTEIN", 212, 215], ["patients", "SPECIES", 132, 140], ["The CD19", "TEST", 0, 8], ["CD3", "TEST", 9, 12], ["B cells", "TEST", 24, 31], ["HC", "TEST", 155, 157], ["cells", "TEST", 175, 180], ["the CD4", "TEST", 199, 206], ["CD8", "TEST", 212, 215], ["CD19", "ANATOMY", 4, 8], ["CD3", "ANATOMY", 9, 12], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["mild", "OBSERVATION_MODIFIER", 65, 69], ["moderate", "OBSERVATION_MODIFIER", 96, 104], ["cell compartment", "OBSERVATION", 219, 235]]], ["There was a tendency 212 of increased CD4+ T cells for outpatients, inpatients and convalescent patients compared to 213 HC, but no significant difference was observed among any of the groups.", [["CD4+ T cells", "ANATOMY", 38, 50], ["CD4", "GENE_OR_GENE_PRODUCT", 38, 41], ["patients", "ORGANISM", 96, 104], ["CD4", "PROTEIN", 38, 41], ["T cells", "CELL_TYPE", 43, 50], ["outpatients", "SPECIES", 55, 66], ["patients", "SPECIES", 96, 104], ["increased CD4+ T cells", "PROBLEM", 28, 50], ["significant difference", "PROBLEM", 132, 154], ["tendency", "OBSERVATION_MODIFIER", 12, 20], ["no", "UNCERTAINTY", 129, 131], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["difference", "OBSERVATION", 144, 154]]], ["CD8+ T cells were 214 significantly different between HC compared to moderate (p=0.04) or convalescent (p=0.04) 215 patients (Fig. 2b) .", [["CD8+ T cells", "ANATOMY", 0, 12], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["patients", "ORGANISM", 116, 124], ["CD8", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["patients", "SPECIES", 116, 124], ["CD8", "TEST", 0, 3], ["T cells", "TEST", 5, 12], ["HC", "TEST", 54, 56], ["moderate", "OBSERVATION_MODIFIER", 69, 77]]], ["Finally, we characterized CD4+Foxp3+CD45R-regulatory T cells (Tregs), 216 however, no significant difference was observed among the different groups (Suppl.", [["CD4+Foxp3+CD45R-regulatory T cells", "ANATOMY", 26, 60], ["Tregs", "ANATOMY", 62, 67], ["CD4", "GENE_OR_GENE_PRODUCT", 26, 29], ["Foxp3", "GENE_OR_GENE_PRODUCT", 30, 35], ["CD45R", "GENE_OR_GENE_PRODUCT", 36, 41], ["CD4", "PROTEIN", 26, 29], ["Foxp3", "PROTEIN", 30, 35], ["CD45R", "PROTEIN", 36, 41], ["regulatory T cells", "CELL_TYPE", 42, 60], ["Tregs", "CELL_TYPE", 62, 67], ["CD4", "TEST", 26, 29], ["Foxp3", "TEST", 30, 35], ["CD45R", "TEST", 36, 41], ["Tregs", "TEST", 62, 67], ["significant difference", "PROBLEM", 86, 108], ["Foxp3+CD45R", "OBSERVATION", 30, 41], ["no", "UNCERTAINTY", 83, 85], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["difference", "OBSERVATION", 98, 108]]], ["Fig. 2 ).218Impaired activation and defective cytotoxic functions of CD8+ T cells220We found that the percentage of CD8+ T cells was decreased in mild and convalescent 221 patients compared to HC.", [["CD8+ T cells", "ANATOMY", 69, 81], ["CD8+ T cells", "ANATOMY", 116, 128], ["CD8", "GENE_OR_GENE_PRODUCT", 69, 72], ["CD8", "GENE_OR_GENE_PRODUCT", 116, 119], ["patients", "ORGANISM", 172, 180], ["CD8", "PROTEIN", 69, 72], ["CD8+ T cells", "CELL_TYPE", 116, 128], ["patients", "SPECIES", 172, 180], ["Impaired activation", "PROBLEM", 12, 31], ["defective cytotoxic functions", "PROBLEM", 36, 65], ["T cells", "TEST", 74, 81], ["CD8", "TEST", 116, 119], ["T cells", "PROBLEM", 121, 128], ["cytotoxic", "OBSERVATION_MODIFIER", 46, 55], ["decreased", "OBSERVATION_MODIFIER", 133, 142], ["mild", "OBSERVATION_MODIFIER", 146, 150]]], ["Thus, we explored the activation status of CD8+ T cells based on 222 HLA-DR expression.", [["CD8+ T cells", "ANATOMY", 43, 55], ["CD8", "GENE_OR_GENE_PRODUCT", 43, 46], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 69, 75], ["CD8", "PROTEIN", 43, 46], ["T cells", "CELL_TYPE", 48, 55]]], ["We found that CD8+ T cell activation status in all three groups of infected 223 patients were significantly different from HC (mild p=0.01, moderate p=0.009, and 224 convalescent p=0.008, Fig. 3a) .", [["CD8+ T cell", "ANATOMY", 14, 25], ["CD8", "GENE_OR_GENE_PRODUCT", 14, 17], ["patients", "ORGANISM", 80, 88], ["CD8", "PROTEIN", 14, 17], ["patients", "SPECIES", 80, 88], ["CD8", "TEST", 14, 17], ["T cell activation status", "PROBLEM", 19, 43], ["HC", "TEST", 123, 125], ["convalescent p", "TEST", 166, 180], ["cell", "OBSERVATION", 21, 25], ["infected", "OBSERVATION_MODIFIER", 67, 75], ["mild", "OBSERVATION_MODIFIER", 127, 131]]], ["We characterized the cytotoxic potential of CD8+ T cells based 225 on granzyme B and perforin levels and found that there was a tendency of decreased 226 granzyme B expression in mild, moderate and convalescent patients compared with HC ( Fig. 227 3b), however it did not reach significance.", [["CD8+ T cells", "ANATOMY", 44, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 44, 47], ["granzyme B", "GENE_OR_GENE_PRODUCT", 70, 80], ["perforin", "GENE_OR_GENE_PRODUCT", 85, 93], ["granzyme B", "GENE_OR_GENE_PRODUCT", 154, 164], ["patients", "ORGANISM", 211, 219], ["CD8", "PROTEIN", 44, 47], ["T cells", "CELL_TYPE", 49, 56], ["granzyme B", "PROTEIN", 70, 80], ["perforin", "PROTEIN", 85, 93], ["granzyme B", "PROTEIN", 154, 164], ["patients", "SPECIES", 211, 219], ["T cells", "PROBLEM", 49, 56], ["granzyme B", "TEST", 70, 80], ["perforin levels", "TEST", 85, 100], ["a tendency of decreased 226 granzyme B expression in mild, moderate and convalescent patients", "PROBLEM", 126, 219], ["HC", "TEST", 234, 236], ["cytotoxic", "OBSERVATION_MODIFIER", 21, 30], ["tendency", "OBSERVATION_MODIFIER", 128, 136], ["decreased", "OBSERVATION_MODIFIER", 140, 149], ["mild", "OBSERVATION_MODIFIER", 179, 183], ["moderate", "OBSERVATION_MODIFIER", 185, 193]]], ["Perforin was significantly decreased in convalescent 228 (p=0.03) patients compared with HC ( Fig. 3b) , although mild patients also had borderline 229 significantly reduced levels (p=0.06).", [["Perforin", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 119, 127], ["HC", "TEST", 89, 91], ["significantly", "OBSERVATION_MODIFIER", 13, 26], ["decreased", "OBSERVATION_MODIFIER", 27, 36], ["mild", "OBSERVATION_MODIFIER", 114, 118]]], ["Furthermore, we studied the expression of CD38, a 230 marker of cell activation, which was significantly upregulated in convalescent patients 231 compared with HC (p=0.01), mild (p=0.03) and moderate (p=0.02) patients (Fig. 4a) .", [["cell", "ANATOMY", 64, 68], ["CD38", "GENE_OR_GENE_PRODUCT", 42, 46], ["cell", "CELL", 64, 68], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 209, 217], ["CD38", "PROTEIN", 42, 46], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 209, 217], ["CD38", "TEST", 42, 46], ["cell activation", "TEST", 64, 79], ["HC", "TEST", 160, 162], ["mild (p=0.03) and moderate (p=0.02) patients (Fig.", "PROBLEM", 173, 223], ["cell activation", "OBSERVATION", 64, 79], ["mild", "OBSERVATION_MODIFIER", 173, 177], ["moderate", "OBSERVATION_MODIFIER", 191, 199]]], ["Similarly, 232 convalescent patients had significantly increased numbers of CD38+PD-1+ cytotoxic CD8+ T 233 cells compared with HC (p=0.005), moderate (p=0.002) and mild (p=0.002), which reflects the 234 exhaustion and non-responsiveness (anergy) of CD8+ T cells (Fig. 4b) .", [["CD38+PD-1+ cytotoxic CD8+ T 233 cells", "ANATOMY", 76, 113], ["CD8+ T cells", "ANATOMY", 250, 262], ["patients", "ORGANISM", 28, 36], ["CD38", "GENE_OR_GENE_PRODUCT", 76, 80], ["PD-1", "GENE_OR_GENE_PRODUCT", 81, 85], ["CD8", "GENE_OR_GENE_PRODUCT", 250, 253], ["CD38", "PROTEIN", 76, 80], ["cytotoxic CD8+ T 233 cells", "CELL_TYPE", 87, 113], ["CD8", "PROTEIN", 250, 253], ["T cells", "CELL_TYPE", 255, 262], ["patients", "SPECIES", 28, 36], ["significantly increased numbers", "PROBLEM", 41, 72], ["CD38", "TEST", 76, 80], ["PD", "TEST", 81, 83], ["cytotoxic CD8", "TEST", 87, 100], ["HC", "TEST", 128, 130], ["p", "TEST", 132, 133], ["the 234 exhaustion", "PROBLEM", 196, 214], ["non-responsiveness", "PROBLEM", 219, 237], ["anergy", "TEST", 239, 245], ["CD8+ T cells", "PROBLEM", 250, 262], ["moderate", "OBSERVATION_MODIFIER", 142, 150], ["mild", "OBSERVATION_MODIFIER", 165, 169]]], ["Overall, our data suggested that CD8+ T cells have reduced activation, diminished expression of cytotoxic 236 molecules such as perforin and granzyme B and severely exhausted phenotype.238Dynamics of metabolites production in mild, moderate and convalescent patient that spectral data from mild and moderate patients formed overlapping clusters clearly distinct 242 from a cluster formed by HC and convalescent patients (Fig. 5b) , indicating a strong difference 243 in metabolite levels between infectious state compared to healthy or recovered state.244Statistical analysis of the four different groups, revealed that 15 metabolites showed p-values 245 < 0.05, with highest significance for metabolites from the energy metabolism (Fig. 5c Table 1 ).", [["T cells", "ANATOMY", 38, 45], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["T cells", "CELL", 38, 45], ["perforin", "GENE_OR_GENE_PRODUCT", 128, 136], ["granzyme B", "GENE_OR_GENE_PRODUCT", 141, 151], ["patient", "ORGANISM", 258, 265], ["patients", "ORGANISM", 308, 316], ["patients", "ORGANISM", 411, 419], ["CD8", "PROTEIN", 33, 36], ["T cells", "CELL_TYPE", 38, 45], ["cytotoxic 236 molecules", "PROTEIN", 96, 119], ["perforin", "PROTEIN", 128, 136], ["granzyme B", "PROTEIN", 141, 151], ["patient", "SPECIES", 258, 265], ["patients", "SPECIES", 308, 316], ["patients", "SPECIES", 411, 419], ["our data", "TEST", 9, 17], ["CD8", "TEST", 33, 36], ["reduced activation", "PROBLEM", 51, 69], ["cytotoxic 236 molecules", "PROBLEM", 96, 119], ["perforin and granzyme B", "PROBLEM", 128, 151], ["severely exhausted phenotype", "PROBLEM", 156, 184], ["metabolites production", "PROBLEM", 200, 222], ["mild, moderate and convalescent", "PROBLEM", 226, 257], ["spectral data", "TEST", 271, 284], ["mild and moderate patients formed overlapping clusters", "PROBLEM", 290, 344], ["a strong difference", "PROBLEM", 443, 462], ["Statistical analysis", "TEST", 555, 575], ["p-values", "TEST", 642, 650], ["the energy metabolism", "PROBLEM", 710, 731], ["reduced", "OBSERVATION_MODIFIER", 51, 58], ["diminished", "OBSERVATION_MODIFIER", 71, 81], ["severely", "OBSERVATION_MODIFIER", 156, 164], ["exhausted phenotype", "OBSERVATION", 165, 184], ["metabolites production", "OBSERVATION", 200, 222], ["mild", "OBSERVATION_MODIFIER", 226, 230], ["moderate", "OBSERVATION_MODIFIER", 232, 240], ["mild", "OBSERVATION_MODIFIER", 290, 294], ["moderate", "OBSERVATION_MODIFIER", 299, 307], ["strong", "OBSERVATION_MODIFIER", 445, 451], ["infectious", "OBSERVATION", 496, 506], ["energy metabolism", "OBSERVATION", 714, 731]]], ["The data indicate a strong consumption of glucose, acetate, formate during 247 infection, while with lactate levels are increased.", [["glucose, acetate, formate", "CHEMICAL", 42, 67], ["infection", "DISEASE", 79, 88], ["lactate", "CHEMICAL", 101, 108], ["glucose", "CHEMICAL", 42, 49], ["acetate", "CHEMICAL", 51, 58], ["formate", "CHEMICAL", 60, 67], ["lactate", "CHEMICAL", 101, 108], ["glucose", "SIMPLE_CHEMICAL", 42, 49], ["acetate", "SIMPLE_CHEMICAL", 51, 58], ["formate", "SIMPLE_CHEMICAL", 60, 67], ["lactate", "SIMPLE_CHEMICAL", 101, 108], ["glucose, acetate", "TREATMENT", 42, 58], ["infection", "PROBLEM", 79, 88], ["lactate levels", "TEST", 101, 115], ["infection", "OBSERVATION", 79, 88], ["increased", "OBSERVATION_MODIFIER", 120, 129]]], ["Furthermore, we also found very high levels 248 of fructose in PBMCs from mild patients, medium concentrations in moderate and, low levels 249 in HC and convalescent patients (Fig. 5c) .", [["PBMCs", "ANATOMY", 63, 68], ["fructose", "CHEMICAL", 51, 59], ["fructose", "CHEMICAL", 51, 59], ["fructose", "SIMPLE_CHEMICAL", 51, 59], ["PBMCs", "CELL", 63, 68], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 166, 174], ["PBMCs", "CELL_TYPE", 63, 68], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 166, 174], ["fructose in PBMCs", "PROBLEM", 51, 68], ["medium concentrations in moderate and, low levels", "PROBLEM", 89, 138], ["mild", "OBSERVATION_MODIFIER", 74, 78], ["medium concentrations", "OBSERVATION_MODIFIER", 89, 110], ["moderate", "OBSERVATION_MODIFIER", 114, 122], ["low levels", "OBSERVATION_MODIFIER", 128, 138]]], ["Furthermore, glutamate was almost abolished in 250 mild and moderate patients, potentially as a consequence of enhanced production of \u03b1-251 ketoglutarate in the TCA cycle in PBMCs via glutamate dehydrogenase (Fig. 5c ).253To find an association between different metabolites, we applied the variable importance of 254 projection (VIP) score.", [["PBMCs", "ANATOMY", 174, 179], ["glutamate", "CHEMICAL", 13, 22], ["\u03b1-251 ketoglutarate", "CHEMICAL", 134, 153], ["glutamate", "CHEMICAL", 184, 193], ["glutamate", "CHEMICAL", 13, 22], ["\u03b1-251 ketoglutarate", "CHEMICAL", 134, 153], ["TCA", "CHEMICAL", 161, 164], ["glutamate", "CHEMICAL", 184, 193], ["glutamate", "SIMPLE_CHEMICAL", 13, 22], ["patients", "ORGANISM", 69, 77], ["\u03b1-251 ketoglutarate", "SIMPLE_CHEMICAL", 134, 153], ["TCA", "SIMPLE_CHEMICAL", 161, 164], ["PBMCs", "CELL", 174, 179], ["glutamate dehydrogenase", "GENE_OR_GENE_PRODUCT", 184, 207], ["PBMCs", "CELL_TYPE", 174, 179], ["glutamate dehydrogenase", "PROTEIN", 184, 207], ["patients", "SPECIES", 69, 77], ["glutamate", "TEST", 13, 22], ["enhanced production of \u03b1-251 ketoglutarate", "PROBLEM", 111, 153], ["glutamate dehydrogenase", "TEST", 184, 207], ["moderate", "OBSERVATION_MODIFIER", 60, 68]]], ["We found that formate and glucose had the highest score compared to265To find an association between different metabolites, we applied the variable importance of 269 projection (VIP) score.", [["formate", "CHEMICAL", 14, 21], ["glucose", "CHEMICAL", 26, 33], ["formate", "CHEMICAL", 14, 21], ["glucose", "CHEMICAL", 26, 33], ["formate", "SIMPLE_CHEMICAL", 14, 21], ["glucose", "SIMPLE_CHEMICAL", 26, 33], ["formate and glucose", "TEST", 14, 33]]], ["We found that formate and glucose had the highest score compared to 270 other metabolites (Fig. 6A) .", [["formate", "CHEMICAL", 14, 21], ["glucose", "CHEMICAL", 26, 33], ["formate", "CHEMICAL", 14, 21], ["glucose", "CHEMICAL", 26, 33], ["formate", "SIMPLE_CHEMICAL", 14, 21], ["glucose", "SIMPLE_CHEMICAL", 26, 33], ["formate and glucose", "TEST", 14, 33]]], ["In order to determine if additional metabolites are positively 271 associated with changes in glucose, lactate and fructose, we performed a pattern hunter 272 analysis for all metabolites.", [["glucose", "CHEMICAL", 94, 101], ["lactate", "CHEMICAL", 103, 110], ["fructose", "CHEMICAL", 115, 123], ["glucose", "CHEMICAL", 94, 101], ["lactate", "CHEMICAL", 103, 110], ["fructose", "CHEMICAL", 115, 123], ["glucose", "SIMPLE_CHEMICAL", 94, 101], ["lactate", "SIMPLE_CHEMICAL", 103, 110], ["fructose", "SIMPLE_CHEMICAL", 115, 123], ["changes in glucose", "PROBLEM", 83, 101], ["lactate", "TEST", 103, 110]]], ["We found that high glucose levels correlated with high formate, dihydroxy acetone phosphate (DAP) into the glycolysis, is correlated positively with lactate glucose (Fig. 6 ).280Discussion:457Statistical analysis459Bar diagrams were prepared using GraphPad Prism 6.0.", [["glucose", "CHEMICAL", 19, 26], ["formate", "CHEMICAL", 55, 62], ["dihydroxy acetone phosphate", "CHEMICAL", 64, 91], ["DAP", "CHEMICAL", 93, 96], ["lactate", "CHEMICAL", 149, 156], ["glucose", "CHEMICAL", 19, 26], ["formate", "CHEMICAL", 55, 62], ["dihydroxy acetone phosphate", "CHEMICAL", 64, 91], ["DAP", "CHEMICAL", 93, 96], ["lactate", "CHEMICAL", 149, 156], ["glucose", "CHEMICAL", 157, 164], ["glucose", "SIMPLE_CHEMICAL", 19, 26], ["formate", "SIMPLE_CHEMICAL", 55, 62], ["dihydroxy acetone phosphate", "SIMPLE_CHEMICAL", 64, 91], ["DAP", "SIMPLE_CHEMICAL", 93, 96], ["lactate", "SIMPLE_CHEMICAL", 149, 156], ["glucose", "SIMPLE_CHEMICAL", 157, 164], ["high glucose levels", "PROBLEM", 14, 33], ["high formate, dihydroxy acetone phosphate", "TREATMENT", 50, 91], ["lactate glucose", "TEST", 149, 164]]], ["FACS data were analysed using one-494One exemplary dot plot is shown per study group.", [["FACS data", "TEST", 0, 9]]], ["The bar diagram shows CD3-CD19+ 495 B cells.", [["CD3-CD19+ 495 B cells", "ANATOMY", 22, 43], ["CD3", "GENE_OR_GENE_PRODUCT", 22, 25], ["CD19", "GENE_OR_GENE_PRODUCT", 26, 30], ["CD3", "PROTEIN", 22, 25], ["CD19", "PROTEIN", 26, 30], ["The bar diagram", "TEST", 0, 15], ["CD3", "TEST", 22, 25], ["CD19", "TEST", 26, 30], ["CD3", "OBSERVATION", 22, 25]]], ["P value <0.001.496B.", [["P value", "TEST", 0, 7]]], ["The CD19-CD3+ lymphocytes were examined for CD4+ and CD8+ T marker expression.497One exemplary dot plot is shown per study group.", [["CD19-CD3+ lymphocytes", "ANATOMY", 4, 25], ["CD4+", "ANATOMY", 44, 48], ["CD19", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD3", "GENE_OR_GENE_PRODUCT", 9, 12], ["CD4", "GENE_OR_GENE_PRODUCT", 44, 47], ["CD8", "GENE_OR_GENE_PRODUCT", 53, 56], ["T", "GENE_OR_GENE_PRODUCT", 58, 59], ["CD19", "PROTEIN", 4, 8], ["CD3", "PROTEIN", 9, 12], ["CD4", "PROTEIN", 44, 47], ["CD8", "PROTEIN", 53, 56], ["The CD19", "TEST", 0, 8], ["lymphocytes", "TEST", 14, 25], ["CD4", "TEST", 44, 47], ["CD8", "TEST", 53, 56], ["CD19", "ANATOMY", 4, 8]]], ["There was statistically significant 498 difference among HC, mild, moderate and convalescent (upper FACS panel).499However, CD8+ T cells were significantly reduced in outpatient and convalescent 500 patients. *P value <0.05.587All the authors have seen the manuscript, substantially contributed and agreed to be co-588 author.590Acknowledgements:592We thank you all the patients who participated in this study and FACS core facility (Klinikum-", [["CD8+ T cells", "ANATOMY", 124, 136], ["CD8", "GENE_OR_GENE_PRODUCT", 124, 127], ["patients", "ORGANISM", 199, 207], ["patients", "ORGANISM", 370, 378], ["CD8", "PROTEIN", 124, 127], ["T cells", "CELL_TYPE", 129, 136], ["patients", "SPECIES", 199, 207], ["patients", "SPECIES", 370, 378], ["HC", "TEST", 57, 59], ["mild, moderate and convalescent", "PROBLEM", 61, 92], ["upper FACS panel", "TEST", 94, 110], ["CD8", "TEST", 124, 127], ["P value", "TEST", 210, 217], ["this study", "TEST", 399, 409], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["moderate", "OBSERVATION_MODIFIER", 67, 75], ["convalescent", "OBSERVATION_MODIFIER", 80, 92]]]], "f80c9d58eca8d8bd26118c9a24983356d0c96a4a": [["INTRODUCTIONSevere acute respiratory syndrome (SARS), caused by the previously unrecognized coronavirus (SARS-CoV), is a highly contagious febrile respiratory illness and also associated with a high mortality rate.", [["respiratory", "ANATOMY", 147, 158], ["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["SARS-CoV)", "DISEASE", 105, 114], ["febrile respiratory illness", "DISEASE", 139, 166], ["coronavirus", "ORGANISM", 92, 103], ["SARS-CoV", "ORGANISM", 105, 113], ["SARS-CoV", "SPECIES", 105, 113], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["the previously unrecognized coronavirus", "PROBLEM", 64, 103], ["a highly contagious febrile respiratory illness", "PROBLEM", 119, 166], ["a high mortality rate", "PROBLEM", 192, 213], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["coronavirus", "OBSERVATION", 92, 103], ["highly", "OBSERVATION_MODIFIER", 121, 127], ["contagious", "OBSERVATION_MODIFIER", 128, 138], ["respiratory illness", "OBSERVATION", 147, 166]]], ["It is the first severe and readily transmissible new disease to emerge in the 21st century.", [["readily transmissible new disease", "PROBLEM", 27, 60], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["transmissible", "OBSERVATION_MODIFIER", 35, 48], ["new", "OBSERVATION_MODIFIER", 49, 52], ["disease", "OBSERVATION", 53, 60]]], ["Dr. Carl Urbani, a Advances in Hospitality and Leisure, Volume 3, 87-104 Copyright r 2007 by Elsevier Ltd.", [["Volume", "TEST", 56, 62]]], ["All rights of reproduction in any form reserved ISSN: 1745-3542/doi:10.1016/S1745-3542(06)03006-2 World Health Organization (WHO) epidemiologist working in Vietnam, submitted a report to the WTO, an affiliation of the United Nations, and identified/named this unknown disease ''SARS'' initially in March for the cases with the onset in February of (WHO, 2003a , however, the health authority in China named the disease ''atypical pneumonia'' (or feidian, the shortened version of its full Chinese name) instead (Wang, 2004) .", [["SARS", "DISEASE", 278, 282], ["pneumonia", "DISEASE", 430, 439]]], ["The first cases of SARS are now known to have emerged in mid-November 2002 in Guangdong Province, China.", [["SARS", "DISEASE", 19, 23], ["SARS", "PROBLEM", 19, 23]]], ["On February 21, 2003 , an infected medical doctor (Dr. Liu) left Guangdong Province and visited Hong Kong for attending a wedding reception.", [["left", "ANATOMY_MODIFIER", 60, 64]]], ["Dr. Liu stayed at the Metropole Hotel in Hong Kong and infected a number of tourists from several parts of the world (WHO, 2003b) .", [["infected", "OBSERVATION", 55, 63]]], ["Subsequently, the disease began spreading around the world along international air travel routes.", [["the disease", "PROBLEM", 14, 25], ["disease", "OBSERVATION", 18, 25]]], ["A few days later, hospitals in Hong Kong, Vietnam, and Singapore began reporting cases.", [["few", "OBSERVATION_MODIFIER", 2, 5]]], ["By late February 2003, SARS was considered an emerging disease (WHO, 2003a) .INTRODUCTIONFrom SARS' appearance in November 2002 to July 11, 2003 , when the WHO declared that owing to the outbreak more than 8,400 individuals were infected by and 813 victims died from the disease (WHO, 2003c) .", [["SARS", "DISEASE", 23, 27], ["SARS", "DISEASE", 94, 98], ["individuals", "ORGANISM", 212, 223]]], ["Most SARS cases have occurred in Mainland China, Hong Kong, Taiwan, and Canada.", [["SARS", "DISEASE", 5, 9], ["Most SARS cases", "PROBLEM", 0, 15]]], ["Mainland China reported the largest number of SARS infections (5,327) and deaths (348), followed by Hong Kong (1,755; 298) and Taiwan (671; 84) (CDC, 2003; WHO, 2003c) .", [["SARS infections", "DISEASE", 46, 61], ["deaths", "DISEASE", 74, 80], ["SARS infections", "PROBLEM", 46, 61], ["largest", "OBSERVATION_MODIFIER", 28, 35], ["number", "OBSERVATION_MODIFIER", 36, 42], ["SARS", "OBSERVATION_MODIFIER", 46, 50], ["infections", "OBSERVATION", 51, 61]]], ["Consequently, SARS caused considerable social disruption and public anxiety, even in area well beyond the outbreak sites (WHO, 2003d) .INTRODUCTIONIn terms of the number of SARS infections and deaths, the severity of the outbreak might seem to be overstated and people's responses might look like over-reacting.", [["SARS", "DISEASE", 14, 18], ["anxiety", "DISEASE", 68, 75], ["SARS infections", "DISEASE", 173, 188], ["deaths", "DISEASE", 193, 199], ["people", "ORGANISM", 262, 268], ["people", "SPECIES", 262, 268], ["SARS", "PROBLEM", 14, 18], ["considerable social disruption", "PROBLEM", 26, 56], ["public anxiety", "PROBLEM", 61, 75], ["SARS infections", "PROBLEM", 173, 188], ["considerable", "OBSERVATION_MODIFIER", 26, 38], ["social disruption", "OBSERVATION", 39, 56]]], ["In contrast to tuberculosis (15,000 people infected and 1,500 dead per year), or car accidents (35,000 people injured and 680 killed in the first 3 months of 2003), SARS killed ''only'' 84 patients in Taiwan (Chen, Jang, & Kim, 2007) .", [["tuberculosis", "DISEASE", 15, 27], ["accidents", "DISEASE", 85, 94], ["SARS", "DISEASE", 165, 169], ["patients", "ORGANISM", 189, 197], ["people", "SPECIES", 36, 42], ["people", "SPECIES", 103, 109], ["patients", "SPECIES", 189, 197], ["tuberculosis", "PROBLEM", 15, 27], ["tuberculosis", "OBSERVATION", 15, 27]]], ["Accordingly, some scholars (e.g., Chen et al., 2007; McKercher & Chon, 2004) point out that people were over-reacting to the SARS epidemic and tourism suffered unnecessary damage.", [["SARS", "DISEASE", 125, 129], ["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98], ["unnecessary damage", "PROBLEM", 160, 178]]], ["However, it seems more interesting and necessary to realize factors out of the cumulative number of fatal cases that caused an enormous panic -which subsequently resulted in the over-reactions.A Nationwide Panic Caused in TaiwanThe SARS epidemic has been characterized by its rapid spread.", [["panic", "DISEASE", 136, 141], ["Panic", "DISEASE", 206, 211], ["SARS", "DISEASE", 232, 236], ["an enormous panic", "PROBLEM", 124, 141], ["The SARS epidemic", "PROBLEM", 228, 245], ["its rapid spread", "PROBLEM", 272, 288], ["enormous", "OBSERVATION_MODIFIER", 127, 135], ["panic", "OBSERVATION", 136, 141], ["rapid", "OBSERVATION_MODIFIER", 276, 281], ["spread", "OBSERVATION_MODIFIER", 282, 288]]], ["Hsieh, Chen, and Hsu (2004) synthesize official reports and describe the rapid spread of the SARS outbreak in Taiwan in detail.", [["SARS", "DISEASE", 93, 97]]], ["The WHO reported 3,947 probable SARS cases with 229 deaths worldwide on April 22, 2003; China, Hong Kong, Singapore, Vietnam, and Toronto, Canada, had the most cases.", [["SARS", "DISEASE", 32, 36], ["deaths", "DISEASE", 52, 58]]], ["Taiwan, meanwhile, had 29 probable cases and no deaths.", [["deaths", "DISEASE", 48, 54], ["deaths", "PROBLEM", 48, 54]]], ["The growth of the numbers of SARS infections seemed to be a typical minor outbreak at that time.", [["SARS infections", "DISEASE", 29, 44], ["SARS infections", "PROBLEM", 29, 44], ["a typical minor outbreak", "PROBLEM", 58, 82], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["numbers", "OBSERVATION_MODIFIER", 18, 25], ["SARS", "OBSERVATION_MODIFIER", 29, 33], ["infections", "OBSERVATION", 34, 44], ["typical", "OBSERVATION_MODIFIER", 60, 67], ["minor", "OBSERVATION_MODIFIER", 68, 73], ["outbreak", "OBSERVATION", 74, 82]]], ["On that day, a new cluster of seven infections in Hoping Hospital in Taipei was reported and it started a chain of local transmissions that cumulated in 116 probable cases and 10 deaths in the following two weeks.", [["infections", "DISEASE", 36, 46], ["deaths", "DISEASE", 179, 185], ["new", "OBSERVATION_MODIFIER", 15, 18], ["seven", "OBSERVATION_MODIFIER", 30, 35], ["infections", "OBSERVATION", 36, 46]]], ["By mid-May, the numbers grew to 264 probable cases and 34 deaths.", [["deaths", "DISEASE", 58, 64]]], ["Subsequently, by June 1, it expanded into 680 probable cases and 81 deaths.", [["deaths", "DISEASE", 68, 74]]], ["In a period of less than one month, more than a sixfold increase in the numbers of SARS infections and victims was erupted rapidly in Taiwan.", [["SARS infections", "DISEASE", 83, 98], ["SARS infections", "PROBLEM", 83, 98], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["numbers", "OBSERVATION_MODIFIER", 72, 79], ["SARS", "OBSERVATION_MODIFIER", 83, 87], ["infections", "OBSERVATION", 88, 98]]], ["The rapid increase rates of reported probable SARS case-patients and deaths undoubtedly would cause a panic nationwide in Taiwan.A Nationwide Panic Caused in TaiwanIn addition to the rapid increase rate of reported probable SARS casepatients, the nationwide panic in Taiwan might also be resulted from a sense of the endless and uncontrolled expansion of the outbreak.", [["SARS", "DISEASE", 46, 50], ["deaths", "DISEASE", 69, 75], ["panic", "DISEASE", 102, 107], ["Panic", "DISEASE", 142, 147], ["SARS", "DISEASE", 224, 228], ["panic", "DISEASE", 258, 263], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["A Nationwide Panic", "PROBLEM", 129, 147], ["SARS casepatients", "PROBLEM", 224, 241], ["panic", "PROBLEM", 258, 263], ["uncontrolled expansion of the outbreak", "PROBLEM", 329, 367], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["uncontrolled", "OBSERVATION_MODIFIER", 329, 341], ["expansion", "OBSERVATION_MODIFIER", 342, 351], ["outbreak", "OBSERVATION_MODIFIER", 359, 367]]], ["As the disease was spreading so rapidly, the health authority in Taiwan enforced many stringent measures in order to contain the outbreak.", [["the disease", "PROBLEM", 3, 14], ["many stringent measures", "TREATMENT", 81, 104], ["disease", "OBSERVATION", 7, 14]]], ["In addition to thermal scanning arrivals from abroad to check for signs of fever induced by SARS, Hsieh et al. (2004) indicate two of the most important stressed measures.", [["fever", "DISEASE", 75, 80], ["SARS", "DISEASE", 92, 96], ["thermal scanning arrivals", "TEST", 15, 40], ["fever", "PROBLEM", 75, 80], ["SARS", "PROBLEM", 92, 96], ["fever", "OBSERVATION", 75, 80]]], ["One measure was reporting, admitting, and hospitalizing all susceptible patients.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80]]], ["The other was the house quarantine of people either those with contacts to the suspected case-patients or arrivals from the affected areas abroad.", [["people", "ORGANISM", 38, 44], ["patients", "ORGANISM", 94, 102], ["people", "SPECIES", 38, 44], ["patients", "SPECIES", 94, 102]]], ["However, on the first hand, hospitals in Taiwan were initially unprepared for and unprotected from the SARS disease.", [["SARS disease", "DISEASE", 103, 115], ["the SARS disease", "PROBLEM", 99, 115]]], ["The patient quarantine rooms, personal protective equipments for health care workers, and general infection control, etc., which had been improved and well prepared professionally later (Esswein et al., 2004) , were relatively insufficient at the beginning of the outbreak.", [["infection", "DISEASE", 98, 107], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["health care workers", "TREATMENT", 65, 84], ["general infection control", "TREATMENT", 90, 115], ["infection", "OBSERVATION", 98, 107]]], ["Since frequent unprotected or inadequately protected patient-to-health care worker interactions and grouping large numbers of ill persons can greatly amplify intrahospital transmission (Gopalakrishna et al., 2004) , almost 73 percent of all traceable infections in Taiwan occurred in hospital settings (Hsieh et al., 2004) .", [["infections", "DISEASE", 251, 261], ["patient", "ORGANISM", 53, 60], ["persons", "ORGANISM", 130, 137], ["patient", "SPECIES", 53, 60], ["persons", "SPECIES", 130, 137], ["all traceable infections", "PROBLEM", 237, 261], ["infections", "OBSERVATION", 251, 261]]], ["It caused inevitably a panic among all medical professions on the frontline in the battle against SARS.", [["panic", "DISEASE", 23, 28], ["SARS", "DISEASE", 98, 102]]], ["On the other hand, the home quarantine of a number of susceptible people was frequently broken (Hsieh et al., 2004) .", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72]]], ["Just as the acquired immune deficiency syndrome (AIDS), it cannot be considered quarantineable not only because of medical but also because of ethical and legal issues (Gensini, Yacoub, & Conti, 2004) .", [["acquired immune deficiency syndrome", "DISEASE", 12, 47], ["AIDS", "DISEASE", 49, 53], ["the acquired immune deficiency syndrome", "PROBLEM", 8, 47], ["ethical and legal issues", "PROBLEM", 143, 167], ["immune deficiency", "OBSERVATION", 21, 38]]], ["Accordingly, a sense of uncontrollability was emerged publicly at the beginning of the SARS outbreak.", [["SARS", "DISEASE", 87, 91], ["uncontrollability", "PROBLEM", 24, 41], ["the SARS outbreak", "PROBLEM", 83, 100]]], ["Furthermore, the local sensationalist media accelerated and amplified the resulted panic from the sense of uncontrollability successfully by focusing their attention on some intrahospital transmission and out-of-supervised quarantine cases.", [["panic", "DISEASE", 83, 88], ["panic", "PROBLEM", 83, 88], ["uncontrollability", "PROBLEM", 107, 124]]], ["This phenomenon was consistent with Mason, Grabowski, and Du's (2005, p.", [["consistent with", "UNCERTAINTY", 20, 35], ["Mason", "OBSERVATION", 36, 41]]], ["17) description of the global media that the media were much less interested in providing accurate information and more concerned with selling copies of their publication through sensationalist but inaccurate stories.A Nationwide Panic Caused in TaiwanAside from the domestic factors, i.e., the rapid increase rate of SARSinfected cases and a sense of out-of-control, it should be noted that there was an international factor as well.", [["Panic", "DISEASE", 230, 235], ["A Nationwide Panic", "PROBLEM", 217, 235], ["SARSinfected cases", "PROBLEM", 318, 336], ["rapid", "OBSERVATION_MODIFIER", 295, 300], ["increase", "OBSERVATION_MODIFIER", 301, 309]]], ["The international factor played a significant role in the enforcement of not only a nationwide panic in Taiwan but also a worldwide panic to the SARS epidemic.A Worldwide Panic and the WHO-Prompted Travel RecommendationsIn order to minimize the global spread of SARS, the WHO issued a series of specific travel advisories -recommending travelers to postpone all but essential travel to designated areas where the risk of exposure to SARS was considered high -against Hong Kong, China, Toronto, and Taiwan, respectively from April 2 to May 17 and especially a ''general travel advisory'' to potential travelers on March 15, 2003 (WHO, 2003d .", [["panic", "DISEASE", 95, 100], ["panic", "DISEASE", 132, 137], ["SARS", "DISEASE", 145, 149], ["Panic", "DISEASE", 171, 176], ["SARS", "DISEASE", 262, 266], ["SARS", "DISEASE", 433, 437], ["a worldwide panic", "PROBLEM", 120, 137], ["SARS", "PROBLEM", 433, 437]]], ["The travel advisories did trigger a chain reaction of public anxiety even in areas well beyond the outbreak sites.", [["anxiety", "DISEASE", 61, 68], ["a chain reaction", "PROBLEM", 34, 50], ["public anxiety", "PROBLEM", 54, 68]]], ["Although the recommendations were respectively removed by the WHO from all the designated areas to which they had applied as the SARS outbreak was successfully curtailed in late June, the hospitality and tourism industry in Asia had been severely hit by the outbreak of the SARS epidemic.A Worldwide Panic and the WHO-Prompted Travel RecommendationsWhile it must be praised for the WHO's substantial actions in controlling the SARS outbreak, strong criticism from authorities of the ''off-limits'' areas, tourism industry, and scholars was directed at the organization.", [["SARS", "DISEASE", 129, 133], ["SARS", "DISEASE", 274, 278], ["Panic", "DISEASE", 300, 305], ["SARS", "DISEASE", 427, 431], ["the SARS outbreak", "PROBLEM", 125, 142], ["the SARS epidemic", "PROBLEM", 270, 287], ["the SARS outbreak", "PROBLEM", 423, 440]]], ["Lakshmanan (2003) (as cited by McKercher & Chon, 2004) well describes the very unusual feature of the SARS outbreak by a statement that ''a panic spread faster than the disease itself.''", [["SARS", "DISEASE", 102, 106], ["panic", "DISEASE", 140, 145], ["panic spread", "PROBLEM", 140, 152], ["the disease itself", "PROBLEM", 165, 183], ["disease", "OBSERVATION", 169, 176]]], ["Most likely, it was partly contributed by the participation of the global media as a role of accelerators and amplifiers in the spread of the worldwide panic.", [["panic", "DISEASE", 152, 157], ["panic", "PROBLEM", 152, 157]]], ["Since the WHO publicized its message about SARS and travel warning by using the global media, however, it could not write word-for-word the article or website commentary, the organization could hardly control the tone or precise nature of any media communication.", [["SARS", "DISEASE", 43, 47], ["SARS", "PROBLEM", 43, 47]]], ["Accordingly, Mason et al. (2005) point out that the way the WHO's global health alert was reported by the world's media is also likely to have contributed to the feeling of worldwide panic.SARS Might RecurTourism industry is still threatened by the possibility of the recurrence of the infectious disease since the WHO has warned that SARS might recur.", [["panic", "DISEASE", 183, 188], ["SARS", "DISEASE", 189, 193], ["infectious disease", "DISEASE", 286, 304], ["SARS", "DISEASE", 335, 339], ["worldwide panic", "PROBLEM", 173, 188], ["the infectious disease", "PROBLEM", 282, 304], ["SARS", "PROBLEM", 335, 339], ["infectious", "OBSERVATION", 286, 296]]], ["Besides, there will be new biological threats whether SARS reappears or not.", [["SARS", "DISEASE", 54, 58], ["SARS", "PROBLEM", 54, 58]]], ["From customers' different patronage decisions in response to the SARS outbreak, they can learn valuable lessons and develop a plague survival strategy for possible emerging epidemic outbreaks in the future.", [["SARS", "DISEASE", 65, 69], ["the SARS outbreak", "PROBLEM", 61, 78], ["a plague survival strategy", "TREATMENT", 124, 150]]], ["Particularly, if customers who continued to patronize a hospitality/ tourism service during the SARS outbreak can be distinguished and identified from those who did not, marketing managers may be able to increase their efforts to attract the most potential customers in case the SARS or similar biological crises emerge someday.Related Research on Crisis ManagementDrawing on insights from crisis management literature, not only the proactive, strategic, holistic approaches to the issue of crises have been proposed and discussed (e.g., Ritchie, 2004) , but generic or specific models for analyzing and developing management strategies have also been proposed (e.g., Faulkner, 2001; Huang & Min, 2002) .", [["SARS", "DISEASE", 96, 100], ["SARS", "DISEASE", 279, 283], ["the SARS", "PROBLEM", 275, 283], ["crisis management", "TREATMENT", 390, 407], ["crises", "PROBLEM", 491, 497], ["management strategies", "TREATMENT", 615, 636]]], ["Aside from the underlying efforts, various crisis cases have been explored, investigated, analyzed, and discussed.", [["various crisis cases", "PROBLEM", 35, 55]]], ["Page, Yeoman, Munro, Connell, & Walker (2006) illustrated complex issues associated with a flu pandemic qualitatively via a case study of scenario planning exercise.Related Research on Crisis ManagementTo the impacts of the SARS outbreak, a number of researchers devoted efforts to the formulation of proactive and recovery management in the tourism industry.", [["SARS", "DISEASE", 224, 228], ["Crisis ManagementTo", "TREATMENT", 185, 204], ["proactive and recovery management", "TREATMENT", 301, 334]]], ["While some (e.g., Chen et al., 2007; Dombey, 2003; McKercher & Chon, 2004; Pine & McKercher, 2004) revealed the impacts of the SARS effects on diverse aspects of the managerial functions, on various sectors of the industry, and/or on different geographical areas, some others (e.g., Chien & Law, 2003; Henderson & Ng, 2004; Tse, So, & Sin, 2006) suggested substantial processes to set up contingency and recovery arrangements for hotel and restaurant management specifically.Purpose of StudyThe purpose of this study is to examine empirically different characteristics between theme park visitors who did and did not visit theme parks during the SARS outbreak period in Taiwan.", [["SARS", "DISEASE", 127, 131], ["SARS", "DISEASE", 646, 650], ["the SARS effects", "PROBLEM", 123, 139], ["this study", "TEST", 506, 516], ["SARS", "OBSERVATION", 127, 131]]], ["Can a significant discriminant function be developed to interpret the differences between respondents who did and did not visit theme parks during the SARS outbreak period in Taiwan on the basis of their personal characteristics? 2.", [["SARS", "DISEASE", 151, 155]]], ["What marketing implications can be derived from theme park visitors' different patronage decisions in response to the SARS outbreak?Sampling DesignThe target population for this study was visitors to the five leading theme parks in Taiwan (i.e., Jenfusan, Leofoo, Yamay, Formosan Aboriginal Culture Village, and Window on China).", [["SARS", "DISEASE", 118, 122], ["the SARS outbreak", "PROBLEM", 114, 131], ["this study", "TEST", 173, 183]]], ["Quota sampling technique was employed to select elements of the research sample from the sampling population based on the official report (Tourism Bureau, 2003) on annual attendance to domestic theme parks in Taiwan in 2002.", [["Quota sampling technique", "TREATMENT", 0, 24]]], ["In order to minimize respondents' recall errors, the field survey for data collection was conducted during the period between June 25 and July 2 in 2003 since the WHO extended its travel recommendation to include Taiwan on May 8 and removed it from the list of postpone-travel areas on June 17.", [["the field survey", "TEST", 49, 65], ["data collection", "TEST", 70, 85]]], ["Junior students from a local university were trained as interviewers for data collection.Sampling DesignInterviewers stationed near the exit gates of the five parks invited departing visitors to participate in this study.", [["data collection", "TEST", 73, 88], ["this study", "TEST", 210, 220]]], ["In addition to the information of respondents' general demographics, their patronage frequency in the last year and whether they visited theme parks in the period of the SARS outbreak, the question content also consisted of scale items to measure ''benefit sought,'' ''product involvement,'' and ''risk perception.''", [["SARS", "DISEASE", 170, 174], ["the SARS outbreak", "PROBLEM", 166, 183]]], ["In the specific interests of this study, McQuarrie and Munson's (1992) eight scale items for the measurement of consumers' ''enduring involvement'' with a product were modified to measure respondents' product involvement with theme parks in this study.", [["this study", "TEST", 29, 39], ["Munson's", "TREATMENT", 55, 63], ["this study", "TEST", 241, 251]]], ["As a result, nine involvement measure items with a five-point Likert scale were designed in the questionnaire.", [["Likert scale", "TEST", 62, 74]]], ["Finally, respondents were asked to subjectively estimate the probability a person will be infected with SARS in each of the three given scenarios, respectively.", [["SARS", "DISEASE", 104, 108], ["person", "SPECIES", 75, 81], ["SARS", "PROBLEM", 104, 108]]], ["The given scenarios were:Research Instrument(1) right now in the theme parks which they had just departed from; (2) participating in outdoor recreational activities if the WHO should again extend its postpone-travel recommendation to include Taiwan; and (3) visiting a theme park in the same period of time described in the second scenario.Research InstrumentRespondents were asked to rate the SARS-infected possibility in each of the scenarios in terms of percentage (from ''0'' to ''100'').Data AnalysisIn order to develop a meaningful discriminant function, possible correlations between respondents' personal characteristics had to be avoided or eliminated first.", [["SARS", "DISEASE", 394, 398], ["infected", "OBSERVATION", 399, 407]]], ["Accordingly, variables representing each of the respondents' personal characteristics were condensed into factors by the technique of principal components analysis.", [["principal components analysis", "TEST", 134, 163]]], ["Internal consistency reliability of the variables contained in each of the factors was assessed.", [["consistency", "OBSERVATION_MODIFIER", 9, 20], ["reliability", "OBSERVATION_MODIFIER", 21, 32]]], ["A value of Cronbach's alpha coefficient greater than .6 generally indicates satisfactory internal consistency reliability (Malhotra, 1999) .", [["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 11, 27], ["A value", "TEST", 0, 7], ["Cronbach's alpha coefficient", "TEST", 11, 39]]], ["Mean of respondents' ratings to consistent variables contained in each of the factors served as the input score of the factor in the process of discriminant analysis.", [["discriminant analysis", "TEST", 144, 165]]], ["Thus, on the one hand, whether or not the respondents visited theme parks during the SARS outbreak was adopted to be the dependant (criterion) variable; on the other, respondents' age, their patronage frequency in the last year, and the factors condensed from scale items of respondents' risk perception, benefit sought, and product involvement were adopted to be the independent variables (predictors) in the developing discriminant function.", [["SARS", "DISEASE", 85, 89]]], ["The significance and validity of the function were assessed based on Wilks' l test and the percentage of cases correctly classified, respectively.", [["Wilks' l test", "TEST", 69, 82]]], ["SPSS 10 was utilized for data processing and the level of significance of .05 was accepted for all statistic tests in this study.RESULTSBy using quota sampling technique, a research sample consisting of 1,255 respondents was obtained from visitors to the five leading theme parks.", [["SPSS", "TEST", 0, 4], ["data processing", "TEST", 25, 40], ["all statistic tests", "TEST", 95, 114], ["this study", "TEST", 118, 128], ["quota sampling technique", "TEST", 145, 169], ["a research sample", "TEST", 171, 188]]], ["The correlation matrices of the benefit and involvement scale items in the procedure of principal components analysis were examined by Bartlett's test of sphericity.", [["involvement scale items", "TREATMENT", 44, 67], ["the procedure", "TREATMENT", 71, 84], ["principal components analysis", "TEST", 88, 117]]], ["Besides, the value of the KMO statistic (.871) was also large (>.5).", [["KMO", "GENE_OR_GENE_PRODUCT", 26, 29], ["large", "OBSERVATION_MODIFIER", 56, 61]]], ["To the involvement scale items, the approximate w 2 statistic was 2653.538 with 36 degrees of freedom, which is also of .000 significance and the value of the KMO statistic was .808.", [["the value", "TEST", 142, 151], ["the KMO statistic", "TEST", 155, 172]]], ["Therefore, the procedure of principal components analysis was considered an appropriate technique for analyzing the data in this study.RESULTSIn order to differentiate between the two categories of respondents, a discriminant function was developed in this study.", [["principal components analysis", "TEST", 28, 57], ["analyzing the data", "TEST", 102, 120], ["this study", "TEST", 124, 134], ["this study", "TEST", 252, 262]]], ["At first, seven independent variables for the subsequent discriminant analysis were identified through the analytical procedures of principal components analysis and Cronbach's alpha test.", [["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 166, 182], ["the subsequent discriminant analysis", "TEST", 42, 78], ["principal components analysis", "TEST", 132, 161], ["Cronbach's alpha test", "TEST", 166, 187]]], ["Tables 2 and 3 show the results of principal components analysis.", [["principal components analysis", "TEST", 35, 64]]], ["Ten benefit scale items and nine involvement scale items were condensed into two benefit factors and two involvement factors, were examined to ensure satisfactory internal consistency reliability and then accepted into the discriminant analysis.", [["the discriminant analysis", "TEST", 219, 244]]], ["As a result, the developed standard canonical discriminant function was:RESULTSwhere if Di>.0285, classify individual i as belonging to ''visitors who did visit theme parks during the SARS outbreak''; otherwise classify individual i as belonging to the other category.", [["SARS", "DISEASE", 184, 188], ["Di", "PROBLEM", 88, 90]]], ["It indicates that the variance in the dependent variable is not largely explained by this model.", [["dependent", "OBSERVATION_MODIFIER", 38, 47], ["variable", "OBSERVATION_MODIFIER", 48, 56], ["not largely explained", "UNCERTAINTY", 60, 81]]], ["This is significant beyond the .05 level.", [["significant", "OBSERVATION_MODIFIER", 8, 19]]], ["Therefore, it is meaningful to interpret the results of the discriminant analysis.", [["the discriminant analysis", "TEST", 56, 81]]], ["Table 4 shows the primary results of the discriminant analysis.", [["the discriminant analysis", "TEST", 37, 62]]], ["The significance of the univariate F ratios indicates that when the independent variables are considered individually, only the respondents' age, their patronage frequency, and risk perception were significant predictors in discriminating between the groups.", [["the univariate F ratios", "TEST", 20, 43]]], ["Besides, the pooled within-groups correlation matrix indicates low correlations between the independent variables.", [["low correlations", "OBSERVATION_MODIFIER", 63, 79]]], ["In this case, multicollinearity was unlikely to be a problem.", [["unlikely to be", "UNCERTAINTY", 36, 50]]], ["The signs of the coefficients associated with the significant predictors suggest that younger age and more experience in visiting theme parks were more likely to result in the respondents visiting theme parks during the SARS outbreak.", [["SARS", "DISEASE", 220, 224], ["the SARS outbreak", "PROBLEM", 216, 233]]], ["Meanwhile, individuals who visited theme parks during the SARS outbreak were also associated with higher risk perception.", [["SARS", "DISEASE", 58, 62], ["the SARS outbreak", "PROBLEM", 54, 71]]], ["The function seems to be of deficient validity if one expects the function to distinguish individuals who had been to theme parks during the SARS outbreak from those who had not, since the predictability of the function is only 11 percent greater than that obtained by chance (i.e., 1/2 \u00bc .50 or 50 percent).FINDINGS AND DISCUSSIONSGenerally speaking, in this study, a statistically significant discriminant function was successfully developed to interpret the differences between respondents who did and did not visit theme parks during the SARS outbreak period in Taiwan on the basis of their personal characteristics.", [["SARS", "DISEASE", 141, 145], ["SARS", "DISEASE", 542, 546], ["deficient validity", "PROBLEM", 28, 46], ["the function", "TEST", 207, 219], ["this study", "TEST", 355, 365], ["seems to be", "UNCERTAINTY", 13, 24]]], ["Moreover, individuals who visited theme parks during the SARS outbreak were also associated with higher risk perception.", [["SARS", "DISEASE", 57, 61], ["the SARS outbreak", "PROBLEM", 53, 70]]], ["Substantial marketing implications can be explored based on the results of the discriminant analysis, although the function seems to be of deficient validity in terms of predictability.", [["the discriminant analysis", "TEST", 75, 100], ["deficient validity", "PROBLEM", 139, 157]]], ["First of all, in case the SARS or similar biological crises emerge in the future, younger and/or frequent consumers should be the focused targets of theme park managers' primary marketing efforts because they are more likely to continue to visit theme parks during the period of epidemic outbreak.", [["SARS", "DISEASE", 26, 30], ["the SARS", "PROBLEM", 22, 30], ["similar biological crises", "PROBLEM", 34, 59], ["epidemic outbreak", "PROBLEM", 279, 296]]], ["Accordingly, a plague survival strategy can be developed with the goal of attracting consumers from the targets.", [["a plague survival strategy", "TREATMENT", 13, 39]]], ["Since the benefits sought by theme park visitors played only a trivial role in their patronage decisions during the SARS outbreak, contents of the promotion projects may not be associated with or restricted to particular benefits of visiting theme parks.", [["SARS", "DISEASE", 116, 120], ["the SARS outbreak", "PROBLEM", 112, 129]]], ["Instead, a series of sales promotions, such as special promotional prices for the admission of large teen groups, cross-promotions with firms providing other products or services to young consumers, or discounted season passes for potential heavy-users, may help theme parks survive the period of epidemic outbreak.FINDINGS AND DISCUSSIONSOne of the results of this study indicates that individuals who continued visiting theme parks during the SARS outbreak were associated with higher risk perception in comparison with those who did not visit theme parks.", [["SARS", "DISEASE", 445, 449], ["epidemic outbreak", "PROBLEM", 297, 314], ["this study", "TEST", 361, 371]]], ["It is interesting to note that Grobe and Douthitt (1995) also obtained similar findings from their research regarding milk consumers' risk perception of the recombinant (synthetic) bovine growth hormone (rbGH).", [["milk", "ANATOMY", 118, 122], ["milk", "ORGANISM_SUBSTANCE", 118, 122], ["bovine", "ORGANISM", 181, 187], ["growth hormone", "GENE_OR_GENE_PRODUCT", 188, 202], ["rbGH", "GENE_OR_GENE_PRODUCT", 204, 208], ["bovine", "SPECIES", 181, 187], ["the recombinant (synthetic) bovine growth hormone", "TREATMENT", 153, 202]]], ["Their findings indicated that consumers who purchase more milk perceive a greater risk than those who purchase less (p.", [["milk", "ORGANISM_SUBSTANCE", 58, 62]]], ["In fact, the theme park visitors' continued patronage or the milk purchasers' greater consumption resulted in, rather than resulted from, their greater risk perception.", [["milk", "ANATOMY", 61, 65], ["milk", "ORGANISM_SUBSTANCE", 61, 65]]], ["In detail, the consistent theme park patronage during the SARS outbreak and milk consumption under the purchasers' psychological resistance to the rbGH injection seem to be caused by individuals' relatively inelastic demands for theme parks or milk.", [["milk", "ANATOMY", 76, 80], ["milk", "ANATOMY", 244, 248], ["SARS", "DISEASE", 58, 62], ["rbGH", "CHEMICAL", 147, 151], ["milk", "ORGANISM_SUBDIVISION", 76, 80], ["rbGH", "SIMPLE_CHEMICAL", 147, 151], ["milk", "ORGANISM_SUBSTANCE", 244, 248], ["the rbGH injection", "TREATMENT", 143, 161]]], ["Therefore, in case the SARS or similar biological crises emerge in the future, the present seems to be the perfect time to build up a valuable database consisting of the customers with inelastic demands for particular hospitality and tourism services.", [["SARS", "DISEASE", 23, 27], ["the SARS", "PROBLEM", 19, 27], ["similar biological crises", "PROBLEM", 31, 56]]], ["Thus, service providers may continuously benefit from the database.", [["the database", "TEST", 54, 66]]], ["The finding that visitors' risk perception of the SARS infection did not largely contribute to their patronage decisions during the SARS outbreak provides indirect evidence that theme park visitors' ''risk attitude'' dominated their ''risk perception'' in their risk response behavior to the SARS epidemic.", [["SARS", "DISEASE", 50, 54], ["infection", "DISEASE", 55, 64], ["SARS", "DISEASE", 132, 136], ["SARS", "DISEASE", 292, 296], ["the SARS infection", "PROBLEM", 46, 64], ["the SARS epidemic", "PROBLEM", 288, 305]]], ["Whereas risk attitude deals with consumers' interpretation of the content of the risk, the seriousness of adverse consequences, or the extent of risk aversion toward a particular crisis, risk perception instead deals with consumers' interpretation of the chance of being exposed to the content of the risk.", [["adverse consequences", "PROBLEM", 106, 126], ["risk aversion", "PROBLEM", 145, 158], ["a particular crisis", "PROBLEM", 166, 185]]], ["Suppose that risk attitude is the true motivator behind theme park visitors' responses to the SARS outbreak.", [["SARS", "DISEASE", 94, 98], ["the SARS outbreak", "PROBLEM", 90, 107]]], ["In such a case, Pennings et al. suggest that even if the probabilities of being exposed to the risk are small, effectively communicating these probabilities will have little influence on consumer behavior.", [["small", "OBSERVATION_MODIFIER", 104, 109]]], ["Chien and Law (2003) suggested substantial processes to minimize hotel employees and guests' possibility of SARS infection and to contain the potential spread of viruses on the hotel property.", [["SARS infection", "DISEASE", 108, 122], ["SARS infection", "PROBLEM", 108, 122], ["viruses", "OBSERVATION", 162, 169]]], ["In addition to actually implementing the processes of risk elimination, it is equally important that management should make efforts to let the potential consumers know and let the customers see, smell, hear, and feel the processes of risk elimination on the property.FINDINGS AND DISCUSSIONSBased on the findings and limitations of this study, several recommendations for further research can be drawn.", [["this study", "TEST", 332, 342], ["further research", "TEST", 372, 388]]], ["First, the roles that both risk perception and risk attitude play in people's responses to severe epidemics or similar biological crises can be further explored.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["severe epidemics", "PROBLEM", 91, 107], ["similar biological crises", "PROBLEM", 111, 136]]], ["Extended from the existing related literature, the following research might be expected to establish a theoretical model -consisting risk perception, risk attitude, and other significant variables -of people's responses to disease outbreaks.", [["people", "ORGANISM", 201, 207], ["people", "SPECIES", 201, 207], ["disease outbreaks", "PROBLEM", 223, 240]]], ["Second, although the significant role of the media in the SARS outbreak has been well discussed in Mason et al. (2005) in terms of the amount of media attention given to the outbreak along the five stages of Hall's (2002) ''issue-attention cycle,'' given a strong averse risk attitude toward particular epidemics or pandemics, issues regarding how and what the media can communicate effectively to the public to have significant influence on their responses to the disease outbreak can be further investigated by the following research.", [["SARS", "DISEASE", 58, 62], ["pandemics", "DISEASE", 316, 325], ["media attention", "TREATMENT", 145, 160], ["pandemics", "PROBLEM", 316, 325], ["the disease outbreak", "PROBLEM", 461, 481], ["significant", "OBSERVATION_MODIFIER", 21, 32]]], ["However, it might be even more important to know how to allure or encourage the media to cease rather than amplify social panic by the above approaches.", [["panic", "DISEASE", 122, 127]]], ["The Singapore case -a well-trusted institute (e.g., tourist board) coordinates related media and tourism sectors to establish a taskforce and working with the national health authority to produce guidelines and to have a hold over the social panic -indicated in Henderson (2003) might not work applicably in elsewhere, however, it did provide a sample of possible domestic problem-solving mechanism.", [["panic", "DISEASE", 242, 247]]], ["Based on the basic framework, a possible international cooperation mechanism might be further discussed and developed.CONCLUSIONIt is clear that the international hospitality and tourism industry will always benefit from researchers' continuing efforts to confront any possible emerging industry crises in the future.", [["clear", "OBSERVATION", 134, 139]]], ["The efforts provide effective suggestions to either the management practitioners or the public policymakers during and after a certain crisis emergence in the industry.", [["the management practitioners", "TREATMENT", 52, 80]]]], "d014af4baaed38c8af3e4cf0e5da4a81c5e27ca7": [["Kinetics of decay were broadly consistent between IgG1 and IgG2 91 subclasses, with IgG3 displaying a more rapid, two phase decline (Extended Data Fig. 92 2).", [["IgG1", "GENE_OR_GENE_PRODUCT", 50, 54], ["IgG2", "GENE_OR_GENE_PRODUCT", 59, 63], ["IgG3", "GENE_OR_GENE_PRODUCT", 84, 88], ["IgG1", "PROTEIN", 50, 54], ["IgG2 91 subclasses", "PROTEIN", 59, 77], ["IgG3", "PROTEIN", 84, 88], ["IgG1", "TEST", 50, 54], ["IgG2", "TEST", 59, 63], ["IgG3", "TEST", 84, 88]]], ["Consistent with a previous report 26 , we find N-specific IgG decays significantly 93 more rapidly than S-specific IgG (t1/2 = 71 and 229 days respectively, p < 0.00001, 94 Fig 1D) .", [["IgG", "GENE_OR_GENE_PRODUCT", 58, 61], ["IgG", "PROTEIN", 58, 61], ["S-specific IgG", "PROTEIN", 104, 118], ["N-specific IgG decays", "TEST", 47, 68], ["S-specific IgG", "TEST", 104, 118]]], ["In contrast to IgG, S-specific IgM and IgA1 fit a two-phase decay, with a 95 more rapid early decay (t1/2 = 55 and 42 days respectively) followed by a slower 96 decay in late convalescence (t1/2 = 118 and >1000 days respectively; Fig 1D) .", [["IgG", "GENE_OR_GENE_PRODUCT", 15, 18], ["S-specific IgM", "GENE_OR_GENE_PRODUCT", 20, 34], ["IgA1", "GENE_OR_GENE_PRODUCT", 39, 43], ["IgG", "PROTEIN", 15, 18], ["S-specific IgM", "PROTEIN", 20, 34], ["IgA1", "PROTEIN", 39, 43], ["IgG", "TEST", 15, 18], ["S-specific IgM", "TEST", 20, 34], ["late", "OBSERVATION_MODIFIER", 170, 174], ["convalescence", "OBSERVATION_MODIFIER", 175, 188]]], ["A 97 comparison of decay rates between neutralising activity and antibody binding 98 demonstrated that early neutralisation decay occurs at a similar rate to the early 99 decline in S, RBD and S1-specific IgM (Fig 1E, Extended Data Fig 2) .", [["RBD", "PROTEIN", 185, 188], ["S1", "PROTEIN", 193, 195], ["IgM", "PROTEIN", 205, 208], ["decay rates", "TEST", 19, 30], ["neutralising activity", "TEST", 39, 60], ["antibody binding", "TEST", 65, 81], ["early neutralisation decay", "PROBLEM", 103, 129], ["RBD", "TEST", 185, 188], ["S1", "TEST", 193, 195], ["specific IgM", "TEST", 196, 208], ["S1", "ANATOMY", 193, 195]]], ["Neutralisation 100 titre at both early and late convalescence was well correlated with serum inhibition of 101 RBD-ACE2 binding and S, S1 and RBD specific IgG, IgM (and to a lesser extent 102 IgA1) responses, as well as with S2 and N specific IgG responses (Extended Data Fig 103 3 ).", [["serum", "ANATOMY", 87, 92], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["S1", "GENE_OR_GENE_PRODUCT", 135, 137], ["RBD", "GENE_OR_GENE_PRODUCT", 142, 145], ["IgG", "GENE_OR_GENE_PRODUCT", 155, 158], ["IgM", "GENE_OR_GENE_PRODUCT", 160, 163], ["IgA1", "GENE_OR_GENE_PRODUCT", 192, 196], ["RBD", "PROTEIN", 111, 114], ["ACE2", "PROTEIN", 115, 119], ["S1", "PROTEIN", 135, 137], ["RBD", "PROTEIN", 142, 145], ["IgG", "PROTEIN", 155, 158], ["IgM", "PROTEIN", 160, 163], ["IgA1", "PROTEIN", 192, 196], ["S2", "PROTEIN", 225, 227], ["IgG", "PROTEIN", 243, 246], ["Neutralisation", "TREATMENT", 0, 14], ["serum inhibition", "TEST", 87, 103], ["RBD", "TEST", 111, 114], ["ACE2 binding", "TEST", 115, 127], ["RBD specific IgG", "TEST", 142, 158], ["IgM", "TEST", 160, 163], ["S1", "ANATOMY", 135, 137]]], ["Neutralising activity during early convalescence was the best correlate of long-104 term maintenance of neutralisation responses (Spearman rho=0.88, p<0.00001; 105 Extended Data Fig 3) .", [["neutralisation responses", "TEST", 104, 128], ["Spearman rho", "TEST", 130, 142]]], ["Serum inhibition of RBD-ACE2 binding and S1-specific IgG 106 responses in early infection were also well correlated with neutralisation titre in late 107 convalescence (Spearman rho=0.79, 0.81, respectively; Extended Data Fig 3) .", [["Serum", "ANATOMY", 0, 5], ["infection", "DISEASE", 80, 89], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 20, 28], ["S1", "GENE_OR_GENE_PRODUCT", 41, 43], ["IgG", "GENE_OR_GENE_PRODUCT", 53, 56], ["RBD", "PROTEIN", 20, 23], ["ACE2", "PROTEIN", 24, 28], ["S1", "PROTEIN", 41, 43], ["IgG 106", "PROTEIN", 53, 60], ["Serum inhibition", "TEST", 0, 16], ["RBD", "TEST", 20, 23], ["ACE2 binding", "TEST", 24, 36], ["S1", "TEST", 41, 43], ["specific IgG", "TEST", 44, 56], ["early infection", "PROBLEM", 74, 89], ["neutralisation titre", "TEST", 121, 141], ["Spearman rho", "TEST", 169, 181], ["RBD", "OBSERVATION", 20, 23], ["early", "OBSERVATION_MODIFIER", 74, 79], ["infection", "OBSERVATION", 80, 89]]]], "PMC7115255": [["IntroductionUltraviolet germicidal irradiation (UVGI) has been used to \u201cscrub\u201d the air in health care facilities and laboratories for many decades.", [["Ultraviolet germicidal", "CHEMICAL", 12, 34], ["UVGI", "CHEMICAL", 48, 52], ["Ultraviolet germicidal", "SIMPLE_CHEMICAL", 12, 34], ["IntroductionUltraviolet germicidal irradiation (UVGI)", "TREATMENT", 0, 53], ["germicidal irradiation", "OBSERVATION", 24, 46]]], ["UVGI is known to be efficacious to varying degrees in controlling the circulation of airborne infectious particles.", [["UVGI", "CHEMICAL", 0, 4], ["airborne infectious particles", "PROBLEM", 85, 114], ["known to be", "UNCERTAINTY", 8, 19], ["efficacious", "OBSERVATION_MODIFIER", 20, 31], ["varying degrees", "OBSERVATION_MODIFIER", 35, 50], ["circulation", "ANATOMY", 70, 81], ["airborne infectious", "OBSERVATION", 85, 104]]], ["Approximately 60% of all UVGI air disinfection systems are installed in health care facilities.", [["all UVGI air disinfection systems", "TREATMENT", 21, 54], ["air disinfection", "OBSERVATION", 30, 46]]], ["Until recently, most of the experimental data that led to the development of UVGI systems were decades old.", [["UVGI systems", "PROBLEM", 77, 89]]], ["Although UV light is known to inactivate microorganisms, limiting their ability to grow and multiply when inhaled or picked up on surfaces, there is insufficient evidence on which to base a decision to rely solely on UVGI as an engineering control for preventing health care-associated tuberculosis (TB) transmission.2", [["tuberculosis", "DISEASE", 286, 298], ["TB", "DISEASE", 300, 302], ["microorganisms", "PROBLEM", 41, 55], ["UVGI", "TREATMENT", 217, 221], ["an engineering control", "TREATMENT", 225, 247], ["associated tuberculosis", "PROBLEM", 275, 298], ["tuberculosis", "OBSERVATION", 286, 298]]]], "809dbbe5c0b628ff4e8c41a9e29947e2744bd871": [["(Emedo et al. 2010 ) Dies kann erreicht werden, indem die Behandlung anhand eines Konzepts erfolgt, das die Leitlinien f\u00fcr langzeitparenterale Ern\u00e4hrung von Kindern ber\u00fccksichtigt (Koletzko et al. 2005) und ein individuelles Behandlungsziel definiert.Ergebnisqualit\u00e4tDie \u00dcberwachung der variablen K\u00f6rperl\u00e4nge/-gr\u00f6\u00dfe, des K\u00f6rpergewichts und der Meilensteine der psychomotorischen Entwicklung erfolgen initial engmaschig, dann in zunehmend gr\u00f6\u00dferen Intervallen.", [["Ergebnisqualit\u00e4tDie \u00dcberwachung der variablen K\u00f6rperl\u00e4nge/-gr\u00f6\u00dfe, des K\u00f6rpergewichts und der Meilensteine der psychomotorischen Entwicklung erfolgen initial engmaschig", "SPECIES", 251, 418]]], ["Bei der heimparenteralen Ern\u00e4hrung mit stabilem Infusionsbedarf und ohne Komplikationen werden regelm\u00e4\u00dfige Untersuchungen einmal im Quartal durchgef\u00fchrt.", [["Bei der heimparenteralen Ern\u00e4hrung mit stabilem Infusionsbedarf und ohne Komplikationen werden regelm\u00e4\u00dfige Untersuchungen einmal im Quartal durchgef\u00fchrt", "SPECIES", 0, 152]]], ["Insbesondere ein Zur\u00fcckbleiben der L\u00e4ngenentwicklung hinter derjenigen gesunder Kinder bzw. der Zielgr\u00f6\u00dfe muss eine unmittelbare Abkl\u00e4rung m\u00f6glicher Ursachen nach sich ziehen (\u25b6 \u00dcbersicht).Intestinale RehabilitationDer Begriff der intestinalen Rehabilitation kommt eigentlich aus der Betreuung erwachsener Patienten, bei denen ein \"Zur\u00fcck zum Normalen\" erfolgen kann.", [["Insbesondere ein Zur\u00fcckbleiben der L\u00e4ngenentwicklung hinter derjenigen gesunder Kinder bzw", "SPECIES", 0, 90], ["Intestinale RehabilitationDer Begriff der intestinalen Rehabilitation kommt eigentlich aus der Betreuung erwachsener Patienten, bei denen ein \"Zur\u00fcck zum Normalen\" erfolgen kann", "SPECIES", 189, 366], ["Insbesondere ein Zur\u00fcckbleiben", "TREATMENT", 0, 30], ["der Zielgr\u00f6\u00dfe muss", "TREATMENT", 92, 110], ["Intestinale RehabilitationDer Begriff der intestinalen Rehabilitation", "TREATMENT", 189, 258]]], ["Bei Kindern mit angeborenen Ursachen f\u00fcr das chronische Darmversagen wird in der Regel von enteraler Adaptation gesprochen, d. h. der Magen-Darm-Trakt entwickelt sich so, dass Funktionen fehlender Darmabschnitte von anderen Abschnitten \u00fcbernommen werden und dass Hyperplasie der D\u00fcnnarmschleimhaut und L\u00e4ngenwachstum der verbliebenen Darmabschnitte die mangelnde Resorption allm\u00e4hlich ausgleichen.", [["Bei Kindern mit angeborenen Ursachen f\u00fcr das chronische Darmversagen wird in der Regel von enteraler Adaptation gesprochen, d. h. der Magen-Darm-Trakt entwickelt sich so, dass Funktionen fehlender Darmabschnitte von anderen Abschnitten \u00fcbernommen werden und dass Hyperplasie der D\u00fcnnarmschleimhaut und L\u00e4ngenwachstum der verbliebenen Darmabschnitte die mangelnde Resorption allm\u00e4hlich ausgleichen", "SPECIES", 0, 396]]], ["Das Potenzial der intestinalen Adaptation von Kurzdarmpatienten ist im Kindesalter wesentlich h\u00f6her als im Erwachsenenalter.", [["Das Potenzial der intestinalen Adaptation von Kurzdarmpatienten ist", "TREATMENT", 0, 67]]], ["U. gef\u00f6rdert werden.", [["U. gef\u00f6rdert", "SPECIES", 0, 12]]], ["B. bei der Mikrovillusinklusionserkrankung.", [["B. bei der Mikrovillusinklusionserkrankung", "ORGANISM", 0, 42], ["B. bei der Mikrovillusinklusionserkrankung", "SPECIES", 0, 42]]]], "775cf908302f9b5f7b1234cb1a7dfd51b6fbe227": [["In 2018, there were 200 hospitals registered in BOSC; these hospitals have registered data in 2018, 2019, and 2020 for comparison purposes.", [["comparison purposes", "TEST", 119, 138]]], ["BOSC monitored a significant drop in both the thrombolysis and thrombectomy cases from January to February in 2020 as compared with the same period in 2019.", [["a significant drop", "PROBLEM", 15, 33], ["the thrombolysis", "TREATMENT", 42, 58], ["thrombectomy", "TREATMENT", 63, 75], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["drop", "OBSERVATION_MODIFIER", 29, 33], ["thrombolysis", "OBSERVATION", 46, 58], ["thrombectomy", "OBSERVATION", 63, 75]]], ["We designed a survey to investigate the major changes in stroke care during the COVID-19 outbreak.", [["stroke", "DISEASE", 57, 63], ["stroke care", "TREATMENT", 57, 68], ["the COVID", "TEST", 76, 85]]], ["A focus on February data for both 2019 and 2020 was selected for this study because the burden of COVID-19 peaked during February in China, and March data were not available at the time of investigation.", [["February data", "TEST", 11, 24], ["this study", "TEST", 65, 75], ["COVID", "TEST", 98, 103], ["investigation", "TEST", 189, 202]]], ["Confirmed or suspected COVID-19 patients identified elsewhere were generally transferred to these designated hospitals for centralized care.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["centralized care", "TREATMENT", 123, 139]]], ["To speed up the investigation, we only asked specific questions on major changes, including the changes in prehospital and in-hospital care of patients with stroke (Appendix).Statistical AnalysisThis is a retrospective and simple descriptive study.", [["stroke", "DISEASE", 157, 163], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["simple descriptive study", "TEST", 223, 247], ["Appendix", "ANATOMY", 165, 173]]], ["Data are presented as actual numbers or as percentages. \u03c7 2 with Yates correction was used to calculate 2-tailed P using Graphpad Prism (version 8.2.1; San Diego, CA).Data Extracted From the National Data PlatformAmong the 280 hospitals in the data registry of BOSC, the numbers of thrombolysis cases did not change significantly in January (3397) and February (3422) of 2019 but dropped significantly from 3638 cases in January 2020 to 2508 in February 2020 (31.1% decrease; P<0.0001).", [["Graphpad Prism (version", "TREATMENT", 121, 144], ["thrombolysis cases", "TEST", 282, 300], ["P", "TEST", 476, 477], ["thrombolysis", "OBSERVATION", 282, 294]]], ["The numbers of thrombectomy cases did not change significantly in January (1334) and February (1298)Characteristics of the Data Sets and the ImpactThere were a total of 227 valid and complete datasets from the survey of the 280 stroke centers.", [["stroke", "DISEASE", 228, 234], ["thrombectomy", "TREATMENT", 15, 27], ["thrombectomy", "OBSERVATION", 15, 27]]], ["The retrieval rate of 81% covers 29 of 31 provinces and municipalities across China.", [["The retrieval rate", "TEST", 0, 18]]], ["Nearly 50% of the hospitals were designated hospitals for COVID-19, as indicated in Table 2 .", [["COVID", "TEST", 58, 63]]], ["The capacity and capability of stroke care was reduced and impaired in the majority of these hospitals.", [["stroke", "DISEASE", 31, 37], ["stroke care", "TREATMENT", 31, 42], ["capacity", "OBSERVATION_MODIFIER", 4, 12], ["capability", "OBSERVATION_MODIFIER", 17, 27]]], ["In 2020, hospital admissions related to stroke dropped by \u224840% as compared with the same period in 2019.", [["stroke", "DISEASE", 40, 46], ["stroke", "PROBLEM", 40, 46]]], ["The majority of the stroke centers have stopped or reduced their efforts in stroke education for the public.", [["stroke", "DISEASE", 20, 26], ["stroke", "DISEASE", 76, 82], ["stroke education", "TREATMENT", 76, 92], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["stroke", "OBSERVATION", 20, 26]]], ["There was no difference in the pattern of changes between hospitals designated for COVID-19 and nondesignated hospitals.Potential Causes of the Observed ChangesAs indicated in Table 3 , patients or patients' families not coming to the hospital is likely the most important factor resulting in reduced hospital admission rate and reduced thrombolysis and thrombectomy cases.", [["patients", "ORGANISM", 186, 194], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 198, 206], ["COVID", "TEST", 83, 88], ["reduced thrombolysis", "TREATMENT", 329, 349], ["thrombectomy cases", "TREATMENT", 354, 372], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["thrombolysis", "OBSERVATION", 337, 349], ["thrombectomy", "OBSERVATION", 354, 366]]], ["Deficiencies in stroke awareness is the second critical factor, as we have discussed in the past in the absence of the pandemic.", [["stroke", "DISEASE", 16, 22], ["Deficiencies in stroke awareness", "PROBLEM", 0, 32], ["stroke", "OBSERVATION", 16, 22], ["pandemic", "OBSERVATION", 119, 127]]], ["[4] [5] [6] Other contributing factors are listed in Table 4 , such as lack of adequate transportation methods, including insufficient ambulance resources.", [["[4] [5] [6]", "SIMPLE_CHEMICAL", 0, 11]]], ["Only a small portion of hospitals closed its fast-track stroke care channels.", [["stroke", "DISEASE", 56, 62], ["small", "OBSERVATION_MODIFIER", 7, 12], ["portion", "OBSERVATION_MODIFIER", 13, 20]]], ["The COVID-19 screening process was considered the major factor that caused the potentially increased door-to-needle time, although we do not have the actual data.", [["The COVID", "TEST", 0, 9], ["the actual data", "TEST", 146, 161]]], ["Febrile patients affected the stroke evaluation process, and insufficient stroke medical staff could also affect door-to-needle time.DiscussionThe major finding of this study was that stroke care in China was significantly affected by the outbreak of COVID-19, with a significant reduction in both thrombolysis and thrombectomy.", [["Febrile", "DISEASE", 0, 7], ["stroke", "DISEASE", 30, 36], ["stroke", "DISEASE", 74, 80], ["stroke", "DISEASE", 184, 190], ["COVID-19", "CHEMICAL", 251, 259], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["Febrile", "PROBLEM", 0, 7], ["the stroke evaluation", "TEST", 26, 47], ["this study", "TEST", 164, 174], ["stroke care", "TREATMENT", 184, 195], ["COVID", "TEST", 251, 256], ["a significant reduction", "TREATMENT", 266, 289], ["both thrombolysis", "TREATMENT", 293, 310], ["thrombectomy", "TREATMENT", 315, 327], ["significant", "OBSERVATION_MODIFIER", 268, 279], ["reduction", "OBSERVATION_MODIFIER", 280, 289], ["both thrombolysis", "OBSERVATION", 293, 310], ["thrombectomy", "OBSERVATION", 315, 327]]], ["The change in the number of treatment cases was consistent between the National Data Registry of BOSC from 280 hospitals and our survey results from 227 hospitals, with a similar drop in the number of thrombolysis and thrombectomy cases (around 25%) in February 2020 as compared with February 2019.", [["a similar drop", "PROBLEM", 169, 183], ["thrombolysis", "TREATMENT", 201, 213], ["thrombectomy cases", "TREATMENT", 218, 236], ["change", "OBSERVATION_MODIFIER", 4, 10], ["thrombolysis", "OBSERVATION", 201, 213], ["thrombectomy", "OBSERVATION", 218, 230]]], ["The most prominent factor was that patients with stroke were not coming to the hospital for various reasons.", [["stroke", "DISEASE", 49, 55], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["stroke", "PROBLEM", 49, 55], ["most prominent", "OBSERVATION_MODIFIER", 4, 18]]], ["The screening process for COVID-19 also interfered with stroke care significantly.Changes in Absolute Number and Rate of Thrombolysis and ThrombectomyWhile we observed a significant drop in the absolute number of thrombolysis and thrombectomy cases, the rate of thrombolysis and thrombectomy increased slightly.", [["stroke", "DISEASE", 56, 62], ["Thrombolysis", "DISEASE", 121, 133], ["COVID-19", "CHEMICAL", 26, 34], ["The screening process", "TEST", 0, 21], ["COVID", "TEST", 26, 31], ["stroke care", "TREATMENT", 56, 67], ["Thrombolysis", "TREATMENT", 121, 133], ["Thrombectomy", "TREATMENT", 138, 150], ["a significant drop", "PROBLEM", 168, 186], ["thrombolysis", "TREATMENT", 213, 225], ["thrombectomy", "TREATMENT", 230, 242], ["thrombolysis", "TREATMENT", 262, 274], ["thrombectomy", "TREATMENT", 279, 291], ["Absolute Number", "OBSERVATION_MODIFIER", 93, 108], ["Thrombolysis", "OBSERVATION", 121, 133], ["Thrombectomy", "OBSERVATION", 138, 150], ["significant", "OBSERVATION_MODIFIER", 170, 181], ["drop", "OBSERVATION_MODIFIER", 182, 186], ["absolute", "OBSERVATION_MODIFIER", 194, 202], ["number", "OBSERVATION_MODIFIER", 203, 209], ["thrombolysis", "OBSERVATION", 213, 225], ["thrombectomy", "OBSERVATION", 230, 242], ["thrombolysis", "OBSERVATION", 262, 274], ["thrombectomy", "OBSERVATION", 279, 291], ["increased", "OBSERVATION_MODIFIER", 292, 301], ["slightly", "OBSERVATION_MODIFIER", 302, 310]]], ["The thrombolysisStrokeJuly 2020 treatment rate increased from 7.9% in February 2019 to 9.4% in February 2020, which is similar to the 8.6% rate reported in the US Get With The Guidelines Registry published in 2017.", [["The thrombolysisStrokeJuly", "TREATMENT", 0, 26], ["treatment rate", "TEST", 32, 46]]], ["7 The thrombectomy rate increased from 2.7% in February 2019 to 3.4% in February 2020, which is similar to the 3.3% rate reported in the United States in 2017 for all patients with ischemic stroke at all hospitals.", [["ischemic stroke", "DISEASE", 181, 196], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["The thrombectomy rate", "TREATMENT", 2, 23], ["ischemic stroke", "PROBLEM", 181, 196], ["thrombectomy", "OBSERVATION", 6, 18], ["ischemic", "OBSERVATION_MODIFIER", 181, 189], ["stroke", "OBSERVATION", 190, 196]]], ["8 While the changes were small, they were statistically significant due to the large sample size.", [["the large sample size", "PROBLEM", 75, 96], ["small", "OBSERVATION_MODIFIER", 25, 30], ["large", "OBSERVATION_MODIFIER", 79, 84], ["sample", "OBSERVATION_MODIFIER", 85, 91], ["size", "OBSERVATION_MODIFIER", 92, 96]]], ["Thus, the drop in the absolute number of thrombolysis and thrombectomy cases is due to the drop in stroke admissions.", [["thrombolysis", "DISEASE", 41, 53], ["stroke", "DISEASE", 99, 105], ["the drop", "PROBLEM", 6, 14], ["thrombolysis", "TREATMENT", 41, 53], ["thrombectomy", "TREATMENT", 58, 70], ["the drop in stroke admissions", "PROBLEM", 87, 116], ["drop", "OBSERVATION_MODIFIER", 10, 14], ["absolute", "OBSERVATION_MODIFIER", 22, 30], ["number", "OBSERVATION_MODIFIER", 31, 37], ["thrombolysis", "OBSERVATION", 41, 53], ["thrombectomy", "OBSERVATION", 58, 70], ["stroke", "OBSERVATION", 99, 105]]], ["The drop in the absolute number of therapeutic interventions likely had a profound negative impact on stroke outcome.", [["stroke", "DISEASE", 102, 108], ["The drop", "PROBLEM", 0, 8], ["therapeutic interventions", "TREATMENT", 35, 60], ["stroke outcome", "PROBLEM", 102, 116], ["drop", "OBSERVATION_MODIFIER", 4, 8], ["absolute", "OBSERVATION_MODIFIER", 16, 24], ["number", "OBSERVATION_MODIFIER", 25, 31], ["profound", "OBSERVATION_MODIFIER", 74, 82], ["negative", "OBSERVATION", 83, 91]]], ["First of all, the stroke-related disability likely increased.", [["stroke", "DISEASE", 18, 24], ["disability", "DISEASE", 33, 43], ["the stroke", "PROBLEM", 14, 24], ["related disability", "PROBLEM", 25, 43], ["stroke", "OBSERVATION", 18, 24], ["increased", "OBSERVATION_MODIFIER", 51, 60]]], ["Based on Table 3 for the data from 227 hospitals, there were 13 144 (34 725-21 581) fewer stroke admissions.", [["stroke", "DISEASE", 90, 96]]], ["Assuming the stroke incidence is unchanged from 2019 to 2020 and assuming a conservative 8% thrombolysis rate, the drop in stroke admissions resulted in 1051 fewer patients being treated with thrombolysis.", [["stroke", "DISEASE", 13, 19], ["stroke", "DISEASE", 123, 129], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["the stroke incidence", "PROBLEM", 9, 29], ["a conservative 8% thrombolysis rate", "TREATMENT", 74, 109], ["thrombolysis", "TREATMENT", 192, 204], ["stroke", "OBSERVATION", 13, 19], ["unchanged", "OBSERVATION_MODIFIER", 33, 42]]], ["Similarly, assuming a conservative 3% thrombectomy rate, \u2248394 fewer patients received thrombectomy intervention.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["a conservative 3% thrombectomy rate", "TREATMENT", 20, 55], ["thrombectomy intervention", "TREATMENT", 86, 111], ["thrombectomy", "OBSERVATION", 38, 50], ["thrombectomy", "OBSERVATION", 86, 98]]], ["Additionally, the patients who were not admitted to the hospital potentially lost the opportunity to have appropriate secondary prevention treatment such as carotid revascularization, anticoagulation for atrial fibrillation, antiplatelet therapies, as well as lipid lowering and blood pressure management.", [["carotid", "ANATOMY", 157, 164], ["atrial", "ANATOMY", 204, 210], ["blood", "ANATOMY", 279, 284], ["atrial fibrillation", "DISEASE", 204, 223], ["patients", "ORGANISM", 18, 26], ["carotid", "MULTI-TISSUE_STRUCTURE", 157, 164], ["atrial", "MULTI-TISSUE_STRUCTURE", 204, 210], ["lipid", "SIMPLE_CHEMICAL", 260, 265], ["blood", "ORGANISM_SUBSTANCE", 279, 284], ["patients", "SPECIES", 18, 26], ["appropriate secondary prevention treatment", "TREATMENT", 106, 148], ["carotid revascularization", "TREATMENT", 157, 182], ["anticoagulation", "TREATMENT", 184, 199], ["atrial fibrillation", "PROBLEM", 204, 223], ["antiplatelet therapies", "TREATMENT", 225, 247], ["lipid lowering", "TREATMENT", 260, 274], ["blood pressure management", "TREATMENT", 279, 304], ["carotid", "ANATOMY", 157, 164], ["revascularization", "OBSERVATION", 165, 182], ["atrial", "ANATOMY", 204, 210], ["fibrillation", "OBSERVATION", 211, 223]]], ["The loss of appropriate secondary stroke prevention would have a significant impact on recurrent stroke rate.", [["stroke", "DISEASE", 34, 40], ["stroke", "DISEASE", 97, 103], ["The loss of appropriate secondary stroke prevention", "PROBLEM", 0, 51], ["recurrent stroke rate", "PROBLEM", 87, 108], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["secondary", "OBSERVATION_MODIFIER", 24, 33], ["stroke", "OBSERVATION", 34, 40], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["recurrent", "OBSERVATION_MODIFIER", 87, 96], ["stroke", "OBSERVATION", 97, 103]]], ["It is important to note that here we present only a 1-month data comparison from <300 hospitals out of a large number of hospitals that have a stroke center in China.Patients Not Coming to the HospitalPatients not coming to the hospital for an immediate evaluation of acute stroke is nothing new; however, this became more prominent during the outbreak of COVID-19.", [["stroke", "DISEASE", 143, 149], ["stroke", "DISEASE", 274, 280], ["COVID-19", "CHEMICAL", 356, 364], ["Patients", "ORGANISM", 166, 174], ["Patients", "SPECIES", 166, 174], ["an immediate evaluation", "TEST", 241, 264], ["acute stroke", "PROBLEM", 268, 280], ["COVID", "TEST", 356, 361], ["stroke", "OBSERVATION", 143, 149], ["acute", "OBSERVATION_MODIFIER", 268, 273], ["stroke", "OBSERVATION", 274, 280], ["new", "OBSERVATION_MODIFIER", 292, 295], ["more prominent", "OBSERVATION_MODIFIER", 318, 332]]], ["On top of a lack of stroke knowledge, the lack of knowledge compounded with fear of the virus made patients with stroke much less likely to seek help.", [["stroke", "DISEASE", 20, 26], ["stroke", "DISEASE", 113, 119], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["the virus", "PROBLEM", 84, 93], ["stroke", "PROBLEM", 113, 119]]], ["The emphasis on social distancing might have inappropriately persuaded patients with acute stroke to avoid in-person medical care.", [["acute stroke", "DISEASE", 85, 97], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["acute stroke", "PROBLEM", 85, 97]]], ["Increased social isolation may also have decreased the chance of friends and family members recognizing that a patient was having a stroke.", [["stroke", "DISEASE", 132, 138], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["a stroke", "PROBLEM", 130, 138], ["social isolation", "OBSERVATION", 10, 26], ["stroke", "OBSERVATION", 132, 138]]], ["Proper education including stroke awareness and COVID-19 knowledge is needed in countries affected by COVID-19.", [["stroke", "DISEASE", 27, 33], ["stroke awareness", "PROBLEM", 27, 43], ["COVID", "TEST", 48, 53]]], ["Stroke awareness education is probably never so important as during a pandemic.", [["Stroke", "DISEASE", 0, 6]]], ["Unfortunately, the majority of the hospitals stopped or reduced stroke awareness education.Patients Not Coming to the HospitalUnder city lockdown, the availability of transportation became severely limited.", [["stroke", "DISEASE", 64, 70], ["Patients", "ORGANISM", 91, 99], ["Patients", "SPECIES", 91, 99]]], ["Stroke priority triage plans should be established for conditions of limited emergency resources.", [["Stroke", "DISEASE", 0, 6]]], ["This could potentially be explained by patients going to the hospital that they would normally go to and not being aware which hospitals were designated as COVID-19 centers.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["Another possibility is the relatively robust system of stroke care networks across China.COVID-19 Screening and Stroke Management ProcessesThe COVID-19 screening process could add a significant barrier to door-to-needle time and groin puncture for timely thrombolysis and thrombectomy.", [["groin", "ANATOMY", 229, 234], ["stroke", "DISEASE", 55, 61], ["Stroke", "DISEASE", 112, 118], ["COVID", "TEST", 89, 94], ["Screening", "TEST", 98, 107], ["Stroke Management", "TREATMENT", 112, 129], ["The COVID", "TEST", 139, 148], ["groin puncture", "TREATMENT", 229, 243], ["timely thrombolysis", "TREATMENT", 248, 267], ["thrombectomy", "TREATMENT", 272, 284], ["stroke", "OBSERVATION", 55, 61], ["groin", "ANATOMY", 229, 234], ["thrombectomy", "OBSERVATION", 272, 284]]], ["During the pandemic, all patients admitted to the hospital needed to have epidemiological screening and relevant examinations, which added a significant in-hospital delay for a time-sensitive disease like stroke.", [["stroke", "DISEASE", 205, 211], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["epidemiological screening", "TEST", 74, 99], ["relevant examinations", "TEST", 104, 125], ["a time-sensitive disease like stroke", "PROBLEM", 175, 211], ["stroke", "OBSERVATION", 205, 211]]], ["When laboratory resources and computed tomography (CT) scanners are occupied by a large number of patients with potential COVID-19, proper resource management needs to prioritize time-sensitive diseases such as stroke and myocardial infarction.", [["myocardial", "ANATOMY", 222, 232], ["stroke", "DISEASE", 211, 217], ["myocardial infarction", "DISEASE", 222, 243], ["patients", "ORGANISM", 98, 106], ["myocardial", "MULTI-TISSUE_STRUCTURE", 222, 232], ["patients", "SPECIES", 98, 106], ["computed tomography (CT) scanners", "TEST", 30, 63], ["potential COVID", "TEST", 112, 127], ["proper resource management", "TREATMENT", 132, 158], ["sensitive diseases", "PROBLEM", 184, 202], ["stroke", "PROBLEM", 211, 217], ["myocardial infarction", "PROBLEM", 222, 243], ["large", "OBSERVATION_MODIFIER", 82, 87], ["stroke", "OBSERVATION", 211, 217], ["myocardial", "ANATOMY", 222, 232], ["infarction", "OBSERVATION", 233, 243]]], ["Due to potential false negative results in the currently available coronavirus serology test, and the fact that many patients may be asymptomatic for COVID-19, the screening process should not delay timely therapy.", [["coronavirus", "ORGANISM", 67, 78], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["coronavirus serology test", "TEST", 67, 92], ["asymptomatic", "PROBLEM", 133, 145], ["COVID", "TEST", 150, 155]]], ["The protocol for infectious disease should be initiated with proper personal protective equipment.", [["infectious disease", "DISEASE", 17, 35], ["The protocol", "TREATMENT", 0, 12], ["infectious disease", "PROBLEM", 17, 35], ["proper personal protective equipment", "TREATMENT", 61, 97]]], ["It is important to note that because hospitals have potentially the highest density of patients with COVID-19, to protect the patient, the patient must wear a mask at all times in the hospital.", [["patients", "ORGANISM", 87, 95], ["patient", "ORGANISM", 126, 133], ["patient", "ORGANISM", 139, 146], ["patients", "SPECIES", 87, 95], ["patient", "SPECIES", 126, 133], ["patient", "SPECIES", 139, 146], ["COVID", "TREATMENT", 101, 106], ["a mask", "TREATMENT", 157, 163]]], ["The scientific evidence indicates that putting a mask on the potential infectious source offers the highest protection 9 ; this is called infectious source control.", [["a mask", "TREATMENT", 47, 53], ["infectious source control", "TREATMENT", 138, 163], ["infectious", "OBSERVATION", 71, 81], ["infectious", "OBSERVATION", 138, 148]]], ["Policies to protect the healthcare team, such as proper application of personal protection equipment for the care team, and patient isolation during evaluation and treatment, added significant time to delivery of time-sensitive stroke treatment.", [["stroke", "DISEASE", 228, 234], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["personal protection equipment", "TREATMENT", 71, 100], ["evaluation", "TEST", 149, 159], ["treatment", "TREATMENT", 164, 173], ["time-sensitive stroke treatment", "TREATMENT", 213, 244]]], ["With the rise of intravenous tissue-type plasminogen activator use and more recently acute stroke thrombectomy, much effort was devoted to optimize the timing of therapeutic delivery.", [["stroke", "DISEASE", 91, 97], ["intravenous tissue-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 17, 62], ["intravenous tissue-type plasminogen activator", "TREATMENT", 17, 62], ["acute stroke thrombectomy", "TREATMENT", 85, 110], ["therapeutic delivery", "TREATMENT", 162, 182], ["rise", "OBSERVATION_MODIFIER", 9, 13], ["intravenous tissue", "OBSERVATION_MODIFIER", 17, 35], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["stroke", "OBSERVATION_MODIFIER", 91, 97], ["thrombectomy", "OBSERVATION", 98, 110]]], ["The current viral pandemic has added new obstacles to the system and requires constant adaptation as our knowledge of the disease, and local resources and policies, changes daily.Resource ManagementResource management is critical during a pandemic.", [["viral pandemic", "DISEASE", 12, 26], ["the disease", "PROBLEM", 118, 129], ["Resource ManagementResource management", "TREATMENT", 179, 217], ["viral pandemic", "OBSERVATION", 12, 26]]], ["Such resources include relevant experts, other assisting personnel, equipment, laboratory examination, and personal protective equipment, etc. As we analyzed the data, we noticed that a small portion of hospitals have closed their stroke care channels.", [["stroke", "DISEASE", 231, 237], ["laboratory examination", "TEST", 79, 101], ["personal protective equipment", "TREATMENT", 107, 136], ["small", "OBSERVATION_MODIFIER", 186, 191]]], ["As we proposed in our recent editorial, it might be beneficial to have designated stroke centers during the crisis to ensure adequate resources are available to offer high-quality stroke care.", [["stroke", "DISEASE", 82, 88], ["stroke", "DISEASE", 180, 186], ["high-quality stroke care", "TREATMENT", 167, 191]]], ["1 The emergency medical service and the public should be informed that suspected stroke patients should be sent to such designated hospitals.RecommendationsBased on the data, we are making the following recommendations for stroke care during the crisis of the COVID-19 pandemic:Recommendations1.", [["stroke", "DISEASE", 81, 87], ["stroke", "DISEASE", 223, 229], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["stroke", "PROBLEM", 81, 87], ["stroke care", "TREATMENT", 223, 234]]], ["Improving stroke awareness during the crisis is the key.", [["stroke", "DISEASE", 10, 16], ["Improving stroke awareness", "PROBLEM", 0, 26], ["stroke", "OBSERVATION", 10, 16]]], ["Stroke awareness education activities should not stop or be reduced; they should be enhanced.", [["Stroke", "DISEASE", 0, 6], ["Stroke awareness education activities", "PROBLEM", 0, 37]]], ["A robust systematic educational network should be established and enhanced to educate patients on what to do during the pandemic.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]], ["Establishing a fast-track COVID-19 screening process for patients with potential stroke is highly desirable.", [["stroke", "DISEASE", 81, 87], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["potential stroke", "PROBLEM", 71, 87], ["stroke", "OBSERVATION", 81, 87]]], ["One practical approach is to have a full chest CT scan together with the head and neck CT angiogram scan for all potential stroke patients.", [["head", "ANATOMY", 73, 77], ["neck", "ANATOMY", 82, 86], ["stroke", "DISEASE", 123, 129], ["head", "ORGANISM_SUBDIVISION", 73, 77], ["neck", "ORGAN", 82, 86], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["a full chest CT scan", "TEST", 34, 54], ["the head and neck CT angiogram scan", "TEST", 69, 104], ["chest", "ANATOMY", 41, 46], ["head", "ANATOMY", 73, 77], ["neck", "ANATOMY", 82, 86], ["stroke", "OBSERVATION", 123, 129]]], ["Existing evidence suggests a good correlation between chest CT scan findings and reverse transcription polymerase chain reaction testing in COVID-19.", [["chest CT scan findings", "TEST", 54, 76], ["reverse transcription polymerase chain reaction", "PROBLEM", 81, 128], ["COVID", "TEST", 140, 145], ["good", "OBSERVATION_MODIFIER", 29, 33], ["chest", "ANATOMY", 54, 59]]], ["10, 11 A positive CT scan appears before symptoms in many cases and before a positive virology test in some patients.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["A positive CT scan", "TEST", 7, 25], ["symptoms", "PROBLEM", 41, 49], ["a positive virology test", "TEST", 75, 99]]], ["11, 12 The initial CT should include bilateral multilobar ground-glass opacification, mainly in the lower lobes, which is not included in the current routine practice for CT scan for patients with stroke.Limitations of the StudyThis is a simple descriptive study.", [["lower lobes", "ANATOMY", 100, 111], ["stroke", "DISEASE", 197, 203], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 100, 111], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["The initial CT", "TEST", 7, 21], ["bilateral multilobar ground-glass opacification", "PROBLEM", 37, 84], ["CT scan", "TEST", 171, 178], ["stroke", "PROBLEM", 197, 203], ["the Study", "TEST", 219, 228], ["a simple descriptive study", "TEST", 236, 262], ["bilateral", "ANATOMY_MODIFIER", 37, 46], ["multilobar", "OBSERVATION_MODIFIER", 47, 57], ["ground-glass opacification", "OBSERVATION", 58, 84], ["lower lobes", "ANATOMY", 100, 111], ["stroke", "OBSERVATION", 197, 203]]], ["We did not investigate the incidence of virus infection among patients with stroke, nor did we investigate whether virus infection affected stroke outcomes.", [["infection", "DISEASE", 46, 55], ["stroke", "DISEASE", 76, 82], ["infection", "DISEASE", 121, 130], ["stroke", "DISEASE", 140, 146], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["virus infection", "PROBLEM", 40, 55], ["stroke", "PROBLEM", 76, 82], ["virus infection affected stroke outcomes", "PROBLEM", 115, 155], ["virus", "OBSERVATION", 40, 45]]], ["The potential reasons for such delays are largely observational.", [["such delays", "PROBLEM", 26, 37]]], ["Further study of these issues is needed.", [["Further study", "TEST", 0, 13]]], ["Another limitation of this study is that the data were obtained from highly selected stroke centers that have been certified by an official certification bureau.", [["stroke", "DISEASE", 85, 91], ["this study", "TEST", 22, 32], ["the data", "TEST", 41, 49]]], ["The mechanism of the increase in the number of thrombolysis and thrombectomy from 2018 to 2019 is unclear.", [["thrombolysis", "TREATMENT", 47, 59], ["thrombectomy", "TREATMENT", 64, 76], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["thrombolysis", "OBSERVATION", 47, 59], ["thrombectomy", "OBSERVATION", 64, 76]]], ["It could have been caused by rapid development of stroke centers in these hospitals or by better data registration.Limitations of the StudyIn conclusion, the COVID-19 outbreak affected stroke care significantly, impairing both prehospital and in-hospital care, resulting in a significant decline in thrombolysis and thrombectomy.", [["stroke", "DISEASE", 50, 56], ["stroke", "DISEASE", 185, 191], ["the COVID", "TEST", 154, 163], ["a significant decline", "PROBLEM", 274, 295], ["thrombolysis", "TREATMENT", 299, 311], ["thrombectomy", "TREATMENT", 316, 328], ["rapid", "OBSERVATION_MODIFIER", 29, 34], ["development", "OBSERVATION_MODIFIER", 35, 46], ["stroke", "OBSERVATION", 50, 56], ["significant", "OBSERVATION_MODIFIER", 276, 287], ["decline", "OBSERVATION", 288, 295], ["thrombolysis", "OBSERVATION", 299, 311], ["thrombectomy", "OBSERVATION", 316, 328]]], ["Patients not coming to the hospital was likely a major limiting factor.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Patients with stroke should be encouraged to come to the hospital and be reassured that they will have infectious disease precautions.", [["stroke", "DISEASE", 14, 20], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["stroke", "PROBLEM", 14, 20], ["infectious disease precautions", "TREATMENT", 103, 133]]], ["Enhanced stroke awareness activities, proper resource management, and stroke center designation during the crisis are needed.", [["stroke", "DISEASE", 9, 15], ["stroke", "DISEASE", 70, 76], ["Enhanced stroke awareness activities", "PROBLEM", 0, 36], ["resource management", "TREATMENT", 45, 64], ["the crisis", "PROBLEM", 103, 113], ["stroke", "OBSERVATION", 9, 15]]], ["Recommendations based on the data are provided.", [["the data", "TEST", 25, 33]]]]}